WO2022144930A1 - Pharmaceutical oral suspensions of riociguat - Google Patents
Pharmaceutical oral suspensions of riociguat Download PDFInfo
- Publication number
- WO2022144930A1 WO2022144930A1 PCT/IN2022/050008 IN2022050008W WO2022144930A1 WO 2022144930 A1 WO2022144930 A1 WO 2022144930A1 IN 2022050008 W IN2022050008 W IN 2022050008W WO 2022144930 A1 WO2022144930 A1 WO 2022144930A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dosage form
- suspension
- amount
- riociguat
- immediate release
- Prior art date
Links
- WXXSNCNJFUAIDG-UHFFFAOYSA-N riociguat Chemical compound N1=C(N)C(N(C)C(=O)OC)=C(N)N=C1C(C1=CC=CN=C11)=NN1CC1=CC=CC=C1F WXXSNCNJFUAIDG-UHFFFAOYSA-N 0.000 title claims abstract description 158
- 229960000529 riociguat Drugs 0.000 title claims abstract description 155
- 239000000725 suspension Substances 0.000 title claims abstract description 136
- 239000002552 dosage form Substances 0.000 claims abstract description 159
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims abstract description 85
- 239000000203 mixture Substances 0.000 claims abstract description 63
- 239000007971 pharmaceutical suspension Substances 0.000 claims abstract description 59
- 238000000034 method Methods 0.000 claims abstract description 31
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- 238000004090 dissolution Methods 0.000 claims abstract description 13
- 239000000375 suspending agent Substances 0.000 claims description 49
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 39
- -1 polyoxyethylene stearate Polymers 0.000 claims description 33
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 27
- 239000000080 wetting agent Substances 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 18
- 239000003002 pH adjusting agent Substances 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 16
- 239000000796 flavoring agent Substances 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 14
- 239000003755 preservative agent Substances 0.000 claims description 14
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 13
- 235000013355 food flavoring agent Nutrition 0.000 claims description 13
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 13
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 13
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 13
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 13
- 239000003765 sweetening agent Substances 0.000 claims description 13
- 235000003599 food sweetener Nutrition 0.000 claims description 12
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 12
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 11
- 239000003085 diluting agent Substances 0.000 claims description 11
- 239000006185 dispersion Substances 0.000 claims description 11
- 235000011187 glycerol Nutrition 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 11
- 229920001285 xanthan gum Polymers 0.000 claims description 11
- 235000010493 xanthan gum Nutrition 0.000 claims description 11
- 239000000230 xanthan gum Substances 0.000 claims description 11
- 229940082509 xanthan gum Drugs 0.000 claims description 11
- 229920002148 Gellan gum Polymers 0.000 claims description 10
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 claims description 10
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 10
- 239000003963 antioxidant agent Substances 0.000 claims description 10
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 10
- 235000010492 gellan gum Nutrition 0.000 claims description 10
- 239000000216 gellan gum Substances 0.000 claims description 10
- 239000012535 impurity Substances 0.000 claims description 10
- 230000002335 preservative effect Effects 0.000 claims description 10
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 claims description 10
- 239000000770 propane-1,2-diol alginate Substances 0.000 claims description 10
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 10
- 230000003078 antioxidant effect Effects 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 9
- 229920001983 poloxamer Polymers 0.000 claims description 9
- 229920000136 polysorbate Polymers 0.000 claims description 9
- 239000001509 sodium citrate Substances 0.000 claims description 9
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 8
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 8
- 239000011230 binding agent Substances 0.000 claims description 8
- 239000003086 colorant Substances 0.000 claims description 8
- 229960000502 poloxamer Drugs 0.000 claims description 8
- 229950008882 polysorbate Drugs 0.000 claims description 8
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 8
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 8
- 239000000600 sorbitol Substances 0.000 claims description 8
- 235000010356 sorbitol Nutrition 0.000 claims description 8
- 239000002518 antifoaming agent Substances 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000008363 phosphate buffer Substances 0.000 claims description 7
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 7
- 229940038773 trisodium citrate Drugs 0.000 claims description 7
- 229930006000 Sucrose Natural products 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 6
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 6
- 229960002216 methylparaben Drugs 0.000 claims description 6
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 6
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 6
- 229960003415 propylparaben Drugs 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 229910019142 PO4 Inorganic materials 0.000 claims description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 5
- 239000007979 citrate buffer Substances 0.000 claims description 5
- 239000008121 dextrose Substances 0.000 claims description 5
- 239000010452 phosphate Substances 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 5
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 5
- 235000010234 sodium benzoate Nutrition 0.000 claims description 5
- 239000004299 sodium benzoate Substances 0.000 claims description 5
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- 239000005715 Fructose Substances 0.000 claims description 4
- 229930091371 Fructose Natural products 0.000 claims description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 238000009826 distribution Methods 0.000 claims description 4
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical class COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 229960001855 mannitol Drugs 0.000 claims description 4
- 229960002920 sorbitol Drugs 0.000 claims description 4
- 229940001496 tribasic sodium phosphate Drugs 0.000 claims description 4
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 4
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 claims description 3
- 108010011485 Aspartame Proteins 0.000 claims description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical class OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 3
- 235000008733 Citrus aurantifolia Nutrition 0.000 claims description 3
- 235000016623 Fragaria vesca Nutrition 0.000 claims description 3
- 240000009088 Fragaria x ananassa Species 0.000 claims description 3
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims description 3
- 101000801619 Homo sapiens Long-chain-fatty-acid-CoA ligase ACSBG1 Proteins 0.000 claims description 3
- 102100033564 Long-chain-fatty-acid-CoA ligase ACSBG1 Human genes 0.000 claims description 3
- 244000246386 Mentha pulegium Species 0.000 claims description 3
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 3
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 3
- 239000004376 Sucralose Substances 0.000 claims description 3
- 240000006909 Tilia x europaea Species 0.000 claims description 3
- 235000011941 Tilia x europaea Nutrition 0.000 claims description 3
- 235000009499 Vanilla fragrans Nutrition 0.000 claims description 3
- 235000012036 Vanilla tahitensis Nutrition 0.000 claims description 3
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 3
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 3
- 240000006365 Vitis vinifera Species 0.000 claims description 3
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 3
- 239000000605 aspartame Substances 0.000 claims description 3
- 235000010357 aspartame Nutrition 0.000 claims description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 3
- 229960003438 aspartame Drugs 0.000 claims description 3
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 3
- 235000010634 bubble gum Nutrition 0.000 claims description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 3
- 238000007908 dry granulation Methods 0.000 claims description 3
- 235000001050 hortel pimenta Nutrition 0.000 claims description 3
- 239000004571 lime Substances 0.000 claims description 3
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 3
- 235000010235 potassium benzoate Nutrition 0.000 claims description 3
- 239000004300 potassium benzoate Substances 0.000 claims description 3
- 229940103091 potassium benzoate Drugs 0.000 claims description 3
- 229940085605 saccharin sodium Drugs 0.000 claims description 3
- 235000019408 sucralose Nutrition 0.000 claims description 3
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 3
- 239000000892 thaumatin Substances 0.000 claims description 3
- 235000010436 thaumatin Nutrition 0.000 claims description 3
- 235000010384 tocopherol Nutrition 0.000 claims description 3
- 229960001295 tocopherol Drugs 0.000 claims description 3
- 229930003799 tocopherol Natural products 0.000 claims description 3
- 239000011732 tocopherol Substances 0.000 claims description 3
- 238000005550 wet granulation Methods 0.000 claims description 3
- XPVAOXNODVEHSC-UHFFFAOYSA-N OC(=O)C1=CC=CC=C1.CCCCOC(=O)C1=CC=C(O)C=C1 Chemical compound OC(=O)C1=CC=CC=C1.CCCCOC(=O)C1=CC=C(O)C=C1 XPVAOXNODVEHSC-UHFFFAOYSA-N 0.000 claims description 2
- 238000001125 extrusion Methods 0.000 claims description 2
- 229960002737 fructose Drugs 0.000 claims description 2
- 238000005469 granulation Methods 0.000 claims description 2
- 230000003179 granulation Effects 0.000 claims description 2
- 238000000265 homogenisation Methods 0.000 claims description 2
- 238000009474 hot melt extrusion Methods 0.000 claims description 2
- 238000005563 spheronization Methods 0.000 claims description 2
- 244000290333 Vanilla fragrans Species 0.000 claims 1
- 238000003556 assay Methods 0.000 abstract description 5
- 230000009747 swallowing Effects 0.000 abstract description 5
- 239000000843 powder Substances 0.000 description 34
- 239000004094 surface-active agent Substances 0.000 description 13
- 239000008187 granular material Substances 0.000 description 12
- 235000002639 sodium chloride Nutrition 0.000 description 11
- 238000009472 formulation Methods 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 235000006708 antioxidants Nutrition 0.000 description 9
- 239000006172 buffering agent Substances 0.000 description 9
- 208000026151 Chronic thromboembolic pulmonary hypertension Diseases 0.000 description 8
- 206010020772 Hypertension Diseases 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 208000002815 pulmonary hypertension Diseases 0.000 description 8
- 235000015165 citric acid Nutrition 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 235000010980 cellulose Nutrition 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- SERLAGPUMNYUCK-YJOKQAJESA-N 6-O-alpha-D-glucopyranosyl-D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-YJOKQAJESA-N 0.000 description 4
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 4
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 230000002085 persistent effect Effects 0.000 description 4
- 230000000306 recurrent effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 208000020925 Bipolar disease Diseases 0.000 description 3
- 239000001692 EU approved anti-caking agent Substances 0.000 description 3
- 208000010228 Erectile Dysfunction Diseases 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 239000005913 Maltodextrin Substances 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 208000032109 Transient ischaemic attack Diseases 0.000 description 3
- 229940081664 adempas Drugs 0.000 description 3
- 239000008365 aqueous carrier Substances 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 3
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 201000001881 impotence Diseases 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- 206010027599 migraine Diseases 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 235000013772 propylene glycol Nutrition 0.000 description 3
- 201000000980 schizophrenia Diseases 0.000 description 3
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 3
- 235000010262 sodium metabisulphite Nutrition 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 150000005846 sugar alcohols Chemical class 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XZKUCJJNNDINKX-HGLHLWFZSA-N (2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4s)-3,4,5-trihydroxy-5-(hydroxymethyl)oxolan-2-yl]methoxy]oxane-3,4,5-triol;hydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)C(O)(CO)O1 XZKUCJJNNDINKX-HGLHLWFZSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- UNXHWFMMPAWVPI-QWWZWVQMSA-N D-threitol Chemical compound OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000237858 Gastropoda Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 229920000569 Gum karaya Polymers 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- NBGXQZRRLOGAJF-UHFFFAOYSA-N Maltulose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)(CO)OCC1O NBGXQZRRLOGAJF-UHFFFAOYSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 240000005561 Musa balbisiana Species 0.000 description 2
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229920001100 Polydextrose Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 235000009827 Prunus armeniaca Nutrition 0.000 description 2
- 244000018633 Prunus armeniaca Species 0.000 description 2
- JVWLUVNSQYXYBE-UHFFFAOYSA-N Ribitol Natural products OCC(C)C(O)C(O)CO JVWLUVNSQYXYBE-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 244000263375 Vanilla tahitensis Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 2
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical compound CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 229920000591 gum Polymers 0.000 description 2
- 229920001903 high density polyethylene Polymers 0.000 description 2
- 239000004700 high-density polyethylene Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 229960004903 invert sugar Drugs 0.000 description 2
- 239000000905 isomalt Substances 0.000 description 2
- 235000010439 isomalt Nutrition 0.000 description 2
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000832 lactitol Substances 0.000 description 2
- 235000010448 lactitol Nutrition 0.000 description 2
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 2
- 229960003451 lactitol Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 2
- 229960000511 lactulose Drugs 0.000 description 2
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 2
- 229920001684 low density polyethylene Polymers 0.000 description 2
- 239000004702 low-density polyethylene Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- 235000012245 magnesium oxide Nutrition 0.000 description 2
- 239000000391 magnesium silicate Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- JCQLYHFGKNRPGE-HFZVAGMNSA-N maltulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-HFZVAGMNSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 229940100692 oral suspension Drugs 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 235000013856 polydextrose Nutrition 0.000 description 2
- 239000001259 polydextrose Substances 0.000 description 2
- 229940035035 polydextrose Drugs 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000000473 propyl gallate Substances 0.000 description 2
- 235000010388 propyl gallate Nutrition 0.000 description 2
- 229940075579 propyl gallate Drugs 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 235000011083 sodium citrates Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 235000021058 soft food Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- ZNEMGFATAVGQSF-UHFFFAOYSA-N 1-(2-amino-6,7-dihydro-4H-[1,3]thiazolo[4,5-c]pyridin-5-yl)-2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]ethanone Chemical compound NC=1SC2=C(CN(CC2)C(CC=2OC(=NN=2)C=2C=NC(=NC=2)NC2CC3=CC=CC=C3C2)=O)N=1 ZNEMGFATAVGQSF-UHFFFAOYSA-N 0.000 description 1
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- NMMKNHWQYKOEJV-UHFFFAOYSA-L C(C)(=O)[O-].[Na+].C(CC(O)(C(=O)O)CC(=O)O)(=O)[O-].[K+] Chemical compound C(C)(=O)[O-].[Na+].C(CC(O)(C(=O)O)CC(=O)O)(=O)[O-].[K+] NMMKNHWQYKOEJV-UHFFFAOYSA-L 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 235000019499 Citrus oil Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N DL-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- YIKYNHJUKRTCJL-UHFFFAOYSA-N Ethyl maltol Chemical compound CCC=1OC=CC(=O)C=1O YIKYNHJUKRTCJL-UHFFFAOYSA-N 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 1
- 241000220225 Malus Species 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- 244000270834 Myristica fragrans Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 235000003893 Prunus dulcis var amara Nutrition 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 240000001987 Pyrus communis Species 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 239000004283 Sodium sorbate Substances 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical compound CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 description 1
- 229960005164 acesulfame Drugs 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910001514 alkali metal chloride Inorganic materials 0.000 description 1
- 229910001617 alkaline earth metal chloride Inorganic materials 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000010617 anise oil Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 239000010620 bay oil Substances 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 235000010237 calcium benzoate Nutrition 0.000 description 1
- 239000004301 calcium benzoate Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- MCFVRESNTICQSJ-RJNTXXOISA-L calcium sorbate Chemical compound [Ca+2].C\C=C\C=C\C([O-])=O.C\C=C\C=C\C([O-])=O MCFVRESNTICQSJ-RJNTXXOISA-L 0.000 description 1
- 235000010244 calcium sorbate Nutrition 0.000 description 1
- 239000004303 calcium sorbate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000001175 calcium sulphate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- HZQXCUSDXIKLGS-UHFFFAOYSA-L calcium;dibenzoate;trihydrate Chemical compound O.O.O.[Ca+2].[O-]C(=O)C1=CC=CC=C1.[O-]C(=O)C1=CC=CC=C1 HZQXCUSDXIKLGS-UHFFFAOYSA-L 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 229940119201 cedar leaf oil Drugs 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229960002798 cetrimide Drugs 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- NFCRBQADEGXVDL-UHFFFAOYSA-M cetylpyridinium chloride monohydrate Chemical compound O.[Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NFCRBQADEGXVDL-UHFFFAOYSA-M 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 239000010500 citrus oil Substances 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- SOROIESOUPGGFO-UHFFFAOYSA-N diazolidinylurea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 description 1
- 229960001083 diazolidinylurea Drugs 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N ethyl acetate Substances CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229940093503 ethyl maltol Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 229940073505 ethyl vanillin Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 239000000451 gelidium spp. gum Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 235000021579 juice concentrates Nutrition 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 229940039371 karaya gum Drugs 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 238000002356 laser light scattering Methods 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229960001708 magnesium carbonate Drugs 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 229960000869 magnesium oxide Drugs 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229940043353 maltol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000001702 nutmeg Substances 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 238000004313 potentiometry Methods 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229940083037 simethicone Drugs 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 235000010226 sodium ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004402 sodium ethyl p-hydroxybenzoate Substances 0.000 description 1
- 239000000176 sodium gluconate Substances 0.000 description 1
- 235000012207 sodium gluconate Nutrition 0.000 description 1
- 229940005574 sodium gluconate Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 239000004296 sodium metabisulphite Substances 0.000 description 1
- LROWVYNUWKVTCU-STWYSWDKSA-M sodium sorbate Chemical compound [Na+].C\C=C\C=C\C([O-])=O LROWVYNUWKVTCU-STWYSWDKSA-M 0.000 description 1
- 235000019250 sodium sorbate Nutrition 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- QYNMSPKSYXPZHG-UHFFFAOYSA-M sodium;4-ethoxycarbonylphenolate Chemical compound [Na+].CCOC(=O)C1=CC=C([O-])C=C1 QYNMSPKSYXPZHG-UHFFFAOYSA-M 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 235000021092 sugar substitutes Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 239000004250 tert-Butylhydroquinone Substances 0.000 description 1
- 235000019281 tert-butylhydroquinone Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000001789 thuja occidentalis l. leaf oil Substances 0.000 description 1
- 239000010678 thyme oil Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
Definitions
- the present invention relates to orally administered, pharmaceutical immediate release suspensions of riociguat.
- the immediate release suspensions are in the form of ready to use suspension and suspension powder for reconstitution. It also relates to the processes for the preparation of said suspensions. It further relates to the use of pharmaceutical suspensions for the treatment of hypertension and related disorders.
- Riociguat is an antihypertensive drug. It is chemically known as methyl 4,6-diamino-2-[l-(2- fluorobenzyl)-lH-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl(methyl)carbamate and is represented by the following formula as:
- Riociguat is marketed in the USA as an immediate release tablet in 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg strengths under the brand name Adempas® by Bayer Healthcare Pharmaceuticals.
- the marketed solid dosage form of riociguat is indicated for the treatment of persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) to improve exercise capacity.
- CTEPH chronic thromboembolic pulmonary hypertension
- PAH pulmonary arterial hypertension
- U.S. Patent No. 10,087,183 assigned to Bayer Healthcare, discloses polymorphs of riociguat such as modification I, modification II, mono-DMSO solvate, sesqui-DMSO solvate, l ⁇ -ethyl acetate solvate and pharmaceutical composition thereof.
- the publication highlights various polymorphic forms of riocugat and the conversion of these polymorphs into other forms.
- U.S. Patent No. 9,884,859 assigned to Sunshine Lake Pharma, discloses crystalline form III and form IV of riociguat.
- Difficulty in swallowing tablets and capsules is a problem for many patients and can induce significant non-compliance with the prescribed treatment regimens.
- Adolescents, children, and the elderly are particularly vulnerable population groups that are more likely than adults to experience difficulty in swallowing tablets or capsules.
- riociguat tablets may be crushed and mixed with water or soft foods for patients who have difficulty in swallowing.
- an extemporaneously created dispersion of riociguat is physicochemically not stable leading to highly variable riociguat dosing with accompanying unpredictable therapeutic efficacy.
- the inventors of the present invention have developed a suspension dosage form of riociguat with an objective to minimize swallowing difficulties, which is likely to improve patient compliance by reducing dysphagia-related adverse events and accordingly providing a more convenient and less cumbersome posology.
- the inventors have developed immediate release, ready to use suspension and/or suspension powder for reconstitution convenient for administration to paediatric and geriatric patients, easy to manufacture, functionally reproducible, and provides ease of dose adjustment.
- the suspension dosage form exhibits desirable technical attributes such as pourability, viscosity, pH, dissolution, re-suspendability, assay and chemical and physical stability.
- the suspension dosage form of the present invention is in the form of immediate release ready to use suspension and/or immediate release suspension powder for reconstitution.
- an immediate release suspension dosage form comprising riociguat for use in the treatment of hypertension, pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension, persistent/recurrent chronic thromboembolic pulmonary hypertension, heart failure, arrhythmia, high blood pressure, angina pectoris, myocardial infarction, stroke, transient ischaemic attacks, arteriosclerosis, erectile dysfunction, osteoporosis, Alzheimer's disease, Parkinson's disease, multiple sclerosis, depression, schizophrenia, bipolar disorder and migraine.
- composition or “formulation” or “dosage form”, as in pharmaceutical composition is intended to encompass a drug product comprising riociguat or its pharmaceutically acceptable salts, esters, solvates, polymorphs, enantiomers or mixtures thereof, and other inert ingredient(s) (pharmaceutically acceptable excipients).
- Such pharmaceutical compositions are synonymous with “formulation” and “dosage form”.
- Pharmaceutical composition of the invention includes, but is not limited to immediate release ready to use suspension, powder for suspension, granules for suspension, pellets, beads, multiparticulates, and the like.
- the pharmaceutical composition refers to powder, granules, pellets, beads, multiparticulates, and the like filled into capsules or sachets, and ready to use suspension.
- the term “ready to use suspension” means a pre-constituted suspension which can be administered as such to patient.
- the “powder for suspension” or “suspension powder for reconstitution” or “dry suspension” or “granules for suspension” are synonymous and are reconstituted with a liquid carrier like water to form a suspension.
- riociguaf is used in broad sense to include not only “riociguaf ’ per se but also its pharmaceutically acceptable salts, solvates, hydrates, enantiomers, derivatives, isomers, polymorphs, stereoisomers, diastereoisomers prodrugs thereof, and also its various crystalline and amorphous forms or mixtures thereof.
- Riociguat is present in an amount from about 0.01% to about 70% of the suspension dosage form, particularly from about 0.01% to about 30%, from about 0.01% to about 20%, from about 0.01% to about 10%, from about 0.01% to about 5%, from about 0.01% to about 3% w/w or w/v of the suspension dosage form.
- excipient means a pharmacologically inactive component such as a suspending agent, pH adjusting agent/buffering agent, diluent, carrier, anticaking agent, antifoaming agent, antioxidant, sweetening agent, flavoring agent, surfactant/solubilizer/wetting agent, buffer, glidant, binder, preservative, and the like.
- Reference to an excipient includes both one and more than one such excipient.
- Co-processed excipients are also covered under the scope of present invention. Combination of excipients performing the same function may also be used to achieve desired formulation characteristics.
- immediate release implies that riociguat is released from the composition in an immediate release fashion.
- Immediate release refers to pharmaceutical compositions that release at least 75% of the active ingredient within a small period of time, typically less than 60 minutes and more particularly in less than 45 minutes and most particularly more than 85% of drug release within 30 minutes.
- the term “about” means ⁇ approximately 10% of the indicated value, such that “about 10 percent” indicates approximately 08 to 12 percent.
- the singular forms “a”, “an”, and “the” include plural references unless the context clearly dictates otherwise.
- a reference to “a process” includes one or more process, and/or steps of the type described herein and/or which will become apparent to those persons skilled in the art upon reading this disclosure and so forth.
- stable refers to chemical stability, wherein not more than 5% w/w of total related substances are formed on storage at 40°C and 75% relative humidity (R.H.) or at 25 °C and 60% R.H. for a period of at least 1 week, for a period of at least one month, particularly for a period of two months, and more particularly for a period of at least three months.
- weight percentages expressed herein are based on the final weight or volume of the composition or formulation.
- a stable immediate release oral pharmaceutical suspension dosage form of riociguat comprising riociguat and at least one or more pharmaceutically acceptable excipients.
- the immediate release oral pharmaceutical suspension dosage form of riociguat is a ready-to-use suspension and suspension powder for reconstitution.
- an immediate release oral pharmaceutical suspension dosage form of riociguat comprising: a) riociguat; b) a suspending agent; and c) at least one or more pharmaceutically acceptable excipients.
- an immediate release oral pharmaceutical suspension dosage form of riociguat comprising: a) riociguat from about 0.01% to about 30% w/w; b) a suspending agent from about 0.05% to about 20% w/w; and c) at least one or more pharmaceutically acceptable excipients.
- an immediate release oral pharmaceutical suspension dosage form of riociguat comprising: a) riociguat from about 0.01% to about 30% w/w; b) a suspending agent from about 0.05% to about 20% w/w; and c) at least one or more pharmaceutically acceptable excipients; wherein the pH of the suspension is from about 3 to about 8.
- an immediate release ready to use oral pharmaceutical suspension of riociguat comprising: a) riociguat from about 0.01% to about 30% w/w; b) a suspending agent from about 0.05% to about 20% w/w; and c) a pharmaceutically acceptable liquid carrier.
- an immediate release oral pharmaceutical suspension powder for reconstitution of riociguat comprising: a) riociguat from about 0.01% to about 30% w/w; b) a suspending agent from about 0.05% to about 20% w/w; and c) one or more pharmaceutically acceptable excipients.
- an immediate release oral pharmaceutical suspension dosage form of riociguat comprising: a) riociguat; b) a suspending agent; and c) at least one or more pharmaceutically acceptable excipients; wherein the dosage form exhibits an in-vitro dissolution rate of more than 50% of drug release within 30 minutes when the said dosage form is placed in a dissolution vessel filled with 900 ml of pH 6.8 phosphate buffer with 0.1% sodium lauryl sulfate (SLS) maintained at 37 ⁇ 0.5°C and stirred at a paddle speed of 75 rpm using a USP Type II (paddle) apparatus.
- SLS sodium lauryl sulfate
- an immediate release oral pharmaceutical suspension powder for reconstitution of riociguat comprising riociguat and a suspending agent, wherein the suspending agent is present in an amount ranging from about 0.05% to about 20% w/w in the powder formulation.
- an immediate release oral pharmaceutical suspension dosage form of riociguat comprising riociguat and a suspending agent, wherein the riociguat and suspending agent have a ratio ranging from about 1 : 0.01 to 1:40 by weight.
- the riociguat and suspending agent have a ratio ranging from about 1:0.01 to 1:50.
- the riociguat and suspending agent have a ratio ranging from about 1 : 10 to 1 :50.
- the riociguat and suspending agent have a ratio ranging from about 1:0.01 to 1:25.
- the riociguat and suspending agent have a ratio of about 1:25. In a preferred embodiment, the riociguat and suspending agent have a ratio of about 1:22.5. In a preferred embodiment, the riociguat and suspending agent have a ratio of about 1 : 10. In a preferred embodiment, the riociguat and suspending agent have a ratio of about 1:5.
- an immediate release oral pharmaceutical suspension dosage form of riociguat comprising riociguat and wetting agent, wherein the riociguat and wetting agent have a ratio ranging from about 1 :0.01 to 1 : 10, preferably, ranging from about 1:0.01 to 1:5.
- the immediate release oral pharmaceutical suspension dosage form of riociguat is a ready-to-use suspension and suspension powder for reconstitution.
- the immediate release oral pharmaceutical suspension dosage form of riociguat wherein riociguat is present in an amount from about 0.05 mg/mL to about 30 mg/mL and viscosity from about 100 cps to about 4000 cps.
- the viscosity of the suspension is from about 100 cps to about 3000 cps.
- the viscosity of the suspension is from about 100 cps to about 1000 cps.
- the amount of riociguat in the suspension ranges from about 0.05 mg/mL to about 7.5 mg/mL.
- the amount of riociguat in the suspension ranges from about 0.05 mg/mL to about 5 mg/mL.
- an immediate release oral pharmaceutical suspension dosage form of riociguat comprising: a) riociguat or its pharmaceutically acceptable salt, ester, hydrate or polymorph thereof; b) a suspending agent; c) a pH adjusting agent; and d) one or more pharmaceutically acceptable excipients.
- an immediate release oral pharmaceutical suspension dosage form of riociguat comprising: a) riociguat or its pharmaceutically acceptable salt, ester, hydrate or polymorph thereof; b) a suspending agent; c) pH adjusting agent to maintain the pH of the composition in the range of about 3 to about 8; d) optionally a surfactant; e) optionally a preservative; and f) one or more pharmaceutically acceptable excipients.
- an immediate release oral pharmaceutical suspension dosage form of riociguat comprising: a) riociguat or its pharmaceutically acceptable salt, ester, hydrate or polymorph thereof; b) a suspending agent; c) a pH adjusting agent to maintain the pH of the composition in the range of about 3 to about 8; and d) a diluent or a pharmaceutically acceptable liquid carrier.
- an immediate release oral pharmaceutical suspension dosage form of riociguat comprising: a) riociguat; b) a suspending agent; c) optionally a pH adjusting agent; and d) one or more pharmaceutically acceptable excipients; wherein the suspending agent is selected from the group comprising of xanthan gum, gellan gum, cellulose and its derivatives, a mixture of carboxymethylcellulose and microcrystalline cellulose, propylene glycol alginate, and combinations thereof.
- an immediate release oral pharmaceutical suspension dosage form of riociguat comprising: a) riociguat or its pharmaceutically acceptable salt, ester, hydrate or polymorph thereof a) a suspending agent; b) a surfactant; c) optionally a preservative; d) optionally an antioxidant; e) pH adjusting agent in sufficient amounts to maintain the pH of the composition in the range of about 3 to about 8; and f) a diluent or a pharmaceutically acceptable liquid carrier.
- an immediate release oral pharmaceutical suspension dosage form of riociguat or its pharmaceutically acceptable salt, ester, hydrate or polymorph thereof with one or more pharmaceutically acceptable excipients comprising riociguat from about 0.05 mg/mL to about 30 mg/mL, wherein the pH of the composition is from about 3 to about 8.
- an immediate release oral pharmaceutical suspension dosage form comprising: a) riociguat in an amount of about 0.01 % to about 30% w/v of the dosage form; b) a suspending agent selected from xanthan gum, mixture of microcrystalline cellulose and sodium carboxymethyl cellulose, propylene glycol alginate, and gellan gum in an amount from about 0.05% to about 20% w/v of the dosage form; c) a wetting agent selected from poloxamer, polysorbate, polyoxyethylene stearate and combination thereof in an amount from about 0.01% to about 5% w/v of the dosage form; d) pH adjusting agent or buffering agent selected from citric acid, trisodium citrate, citrate buffer, monosodium dibasic phosphate, tribasic sodium phosphate and combination thereof in an amount from about 0.01% to about 5% w/v of the dosage form; e) a pharmaceutically acceptable liquid carrier selected from water,
- an immediate release oral pharmaceutical suspension dosage form comprising: a) riociguat in an amount of about 0.01% to about 5% w/v of the dosage form; b) a suspending agent selected from xanthan gum, mixture of microcrystalline cellulose and sodium carboxymethyl cellulose, propylene glycol alginate, and gellan gum in an amount from about 0.05% to about 3% w/v of the dosage form; c) a wetting agent selected from poloxamer, polysorbate, polyoxyethylene stearate and combination thereof in an amount from about 0.01% to about 2% w/v of the dosage form; d) liquid carrier selected from water, glycerin and combination thereof in an amount from about 10% to about 95% w/v of the dosage form; and e) at least one or more other pharmaceutically acceptable excipients; wherein the pH of the suspension is from 3 to 6 and suspension exhibits an in-vitro dissolution rate of more than 85%
- an immediate release oral pharmaceutical suspension dosage form comprising: a) riociguat in an amount of about 0.01% to about 5% w/v of the dosage form; b) a suspending agent selected from xanthan gum, mixture of microcrystalline cellulose and sodium carboxymethyl cellulose, propylene glycol alginate, and gellan gum in an amount from about 0.05% to about 3% w/v of the dosage form; c) a wetting agent selected from poloxamer, polysorbate, polyoxyethylene stearate and combination thereof in an amount from about 0.01% to about 2% w/v of the dosage form; d) citric acid in an amount from about 0.01% to about 2% w/v of the dosage form; e) trisodium citrate in an amount from about 0.01% to about 2% w/v of the dosage form; f) sorbitol in an amount from about 0.01% to about 11% w/v of the dosage form;
- an immediate release oral pharmaceutical suspension dosage form comprising: a) riociguat in an amount of about 0.01% to about 5% w/v of the dosage form, b) xanthan gum in an amount from about 0.05% to about 3% w/v of the dosage form; c) polysorbate 80 in an amount from about 0.01 % to about 2% w/v of the dosage form; d) citric acid in an amount from about 0.01 % to about 2% w/v of the dosage form, e) trisodium citrate in an amount from about 0.01% to about 2% w/v of the dosage form; f) sorbitol in an amount from about 0.01% to about 11% w/v of the dosage form; g) sodium benzoate in an amount from about 0.01% to about 1% w/v of the dosage form; h) thaumatin in an amount from about 0.01% to about 2% w/v of
- an immediate release oral pharmaceutical suspension dosage form comprising: a) riociguat in an amount of about 0.05 mg/mL to about 7.5 mg/mL of the dosage form; b) a suspending agent selected from xanthan gum, mixture of microcrystalline cellulose and sodium carboxymethyl cellulose, propylene glycol alginate, and gellan gum in an amount from about 0.1 mg/ml to about 10 mg/ml of the dosage form; c) a wetting agent selected from poloxamer, polysorbate, polyoxyethylene stearate and combination thereof in an amount about 0.01 mg/ml to about 5 mg/ml of the dosage form; d) pH adjusting agent or buffering agent selected from citric acid, trisodium citrate, citrate buffer, monosodium dibasic phosphate, tribasic sodium phosphate and combination thereof in an amount from about 0.01 mg/ml to about 5 mg/ml of the dosage form; and e) a suspending agent selected from xanthan gum, mixture of
- an immediate release oral pharmaceutical suspension dosage form which exhibits an in-vitro dissolution rate of more than 85% of drug release within 30 minutes, when measured in 900 ml of 6.8 phosphate buffer and 0.1% sodium lauryl sulfate (SLS) using a USP II apparatus (Paddle) at a temperature of 37 ⁇ 0.5°C and a rotation speed of 75 revolutions
- an immediate release oral pharmaceutical suspension dosage form comprises one or more sweetening agents selected from the group consisting of sucrose, dextrose, sucralose, sorbitol, fructose, mannitol, saccharin sodium, aspartame, thaumatin and combination thereof in an amount of about 0.1% w/w to about 20% w/w or w/v of the dosage form.
- an immediate release oral pharmaceutical suspension dosage form comprises one or more preservatives selected from the group consisting of parabens such as methylparaben, propylparaben, butylparaben benzoic acid, sodium benzoate, potassium benzoate, butylated hydroxyl toluene, butylated hydroxyl anisole, tocopherol, benzalkonium chloride and combination thereof in an amount of about 0.001% w/w to about 3% w/w or w/v of the dosage form.
- parabens such as methylparaben, propylparaben, butylparaben benzoic acid, sodium benzoate, potassium benzoate, butylated hydroxyl toluene, butylated hydroxyl anisole, tocopherol, benzalkonium chloride and combination thereof in an amount of about 0.001% w/w to about 3% w/w or w/v of the dosage form.
- an immediate release oral pharmaceutical suspension dosage form comprises one or more flavoring agents selected from the group consisting of orange, grape, lime, vanilla, bubble gum, peppermint, tutti-frutti, strawberry, and combination thereof in an amount of about 0.01% w/w to about 5% w/w of the dosage form.
- the dosage form comprises one or more flavoring agents in an amount from about 0.01% to about 1% w/w or w/v of the dosage form.
- an immediate release oral pharmaceutical suspension dosage form of riociguat comprising riociguat from about 0.05 mg/mL to about 30 mg/mL, wherein the pH of the composition is from about 3 to about 8 and viscosity from about 100 cps to about 4000 cps.
- an immediate release oral pharmaceutical suspension dosage form of riociguat comprising riociguat about lmg/5 mL.
- an immediate release oral pharmaceutical suspension dosage form of riociguat comprising riociguat about 1 mg/mL.
- an immediate release oral pharmaceutical suspension dosage form of riociguat wherein the composition is free from other polymorphic forms.
- a suspension powder for reconstitution of riociguat comprising riociguat and at least one or more pharmaceutically acceptable excipients selected from the group comprising a suspending agent, pH adjusting agent/buffer, antioxidant, anticaking agent, antifoaming agent, coloring agent, sweetening agent, flavouring agent, surfactant/wetting agent, diluent, carrier, glidant, binder, and preservative.
- a ready to use suspension of riociguat comprising riociguat, a pharmaceutically acceptable carrier and at least one or more pharmaceutically acceptable excipients selected from the group comprising of: suspending agent, antioxidant, anticaking agent, antifoaming agent, pH adjusting agent/buffer, coloring agent, sweetening agent, flavouring agent, surfactant/wetting agent, diluent, glidant, binder, and preservative.
- a dry powder for suspension compositions of riociguat suitable for use as a liquid suspension for children or elderly patients.
- an immediate release oral pharmaceutical suspension dosage form of riociguat which is stable.
- a process for the preparation of a ready to use suspension of riociguat comprising combining various components using conventional equipment such as overhead stirrers, ultrasonifiers, mills, homogenizers. Many different orders of addition of components can be employed.
- a process for the preparation of a suspension powder for reconstitution of riociguat comprising admixing riociguat granules with at least one or more pharmaceutically acceptable excipients selected from the group comprising of suspending agent, pH adjusting agent/buffer, diluent, carrier, antioxidant, anticaking agent, antifoaming agent, coloring agent, sweetening agent, flavoring agent, surfactant/solubilizer/wetting agent, preservative, glidant, binder, disintegrant, antioxidant, and mixtures thereof to form a dry admixture, and transferring the dry admixture to a sealable storage container.
- suspending agent pH adjusting agent/buffer, diluent, carrier, antioxidant, anticaking agent, antifoaming agent, coloring agent, sweetening agent, flavoring agent, surfactant/solubilizer/wetting agent, preservative, glidant, binder, disintegrant, antioxidant, and mixtures thereof to form
- a pharmaceutical suspension dosage form of riociguat wherein riociguat has a particle size distribution D90 less than about 200 pm, D50 is less than about 100 pm and Dio is less than about 50 pm.
- D90 of riociguat ranges about 0.1 pm to 200 pm, particularly from 1 pm to 150 pm, 1 pm to 100 pm, from about 1 pm to about 75 pm, particularly from about 1 pm to about 50 pm, particularly from about 1 pm to about 30 pm, particularly from about 1 pm to about 20 pm, more particularly from 1 pm to about 10 pm, and more particularly from 1 pm to about 6.7 pm.
- D50 ranges from about 1 pm to about 100 pm.
- the particle size of riociguat can be measured by suitable techniques such as Laser light scattering (e.g. Malvern Light Scattering), Coulter counter, microscopy and any other technique known in the art.
- an immediate release pharmaceutical suspension dosage form comprising riociguat for use in the treatment of hypertension, persistent/recurrent chronic thromboembolic pulmonary hypertension, pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension, heart failure, arrhythmia, high blood pressure, angina pectoris, myocardial infarction, stroke, transient ischaemic attacks, arteriosclerosis, erectile dysfunction, osteoporosis, Alzheimer's disease, Parkinson's disease, multiple sclerosis, depression, schizophrenia, bipolar disorder and migraine.
- an immediate release oral pharmaceutical suspension dosage form of riociguat wherein the pH of the suspension is in the range of about 3-9.
- the pH is in a range of about 3 to about 8. More preferably, the pH is in a range of about 3 to about 6. More preferably, the pH is in a range of about 3 to about 5.5.
- an immediate release oral pharmaceutical suspension dosage form of riociguat wherein the suspension dosage form comprises less than 2% of total impurities, preferably less than 1% of total impurities.
- the dosage form comprises less than 0.5% of carbamate impurity.
- the dosage form comprises less than 0.5% of des-fluoro impurity.
- the dosage form comprises less than 0.5% of dimethyl impurity.
- the dosage form comprises less than 0.5% of methyl isopropyl impurity.
- the immediate release pharmaceutical suspension dosage form comprises less than 2% of total impurities and less than 0.5% of carbamate impurity.
- riociguat is the sole active ingredient in the suspension dosage form.
- the suspension dosage form of riociguat of the present invention is sugar free.
- the suspension dosage form of riociguat is microbiologically stable.
- an immediate release suspension dosage form comprising riociguat, wherein the suspension is a ready to use suspension packaged in a bottle.
- an immediate release suspension dosage form comprising riociguat, wherein the suspension is a powder for suspension packaged in a bottle or a sachet.
- a process for the preparation of a suspension dosage form comprising riociguat, wherein the process utilized is mixing, blending, dry granulation, wet granulation, hot-melt extrusion process, extrusion spheronization, fluidized bed granulation, dispersion, homogenization or the like.
- a process for preparation of a ready to use suspension of riociguat comprising the following steps: (i) dissolving/dispersing one or more pharmaceutically acceptable excipients in a portion of water;
- step (ii) dispersing riociguat in the mixture of step (i) to form a dispersion
- step (iv) adding the mixture of step (iii) to the dispersion of step (ii);
- step (v) optionally adding one or more pharmaceutically acceptable excipients to the dispersion of step (iv);
- step (vi) optionally homogenizing the mixture of step (iv) to form a suspension.
- process for preparation of a suspension powder for reconstitution of riociguat comprising the following steps:
- step (ii) granulating the mixture of step (i) using a solvent
- step (iii) drying the granulated mixture of step (ii);
- step (iv) milling the mixture of step (iii) to form granules
- step (v) mixing the granules of step (iv) optionally with one or pharmaceutically acceptable excipients to form the suspension powder for reconstitution.
- step (ii) compacting the mixture of step (i) to form slugs
- step (iii) milling the slugs of step (ii) to form granules
- step (iv) mixing the granules of step (iii) optionally with one or pharmaceutically acceptable excipients to form the suspension powder for reconstitution.
- powder/granules for oral suspension can be reconstituted using water or powder/granules for oral suspension can be administered by sprinkling the powder/granules on soft food like yoghurt, applesauce or empty granules into a small cup or teaspoon containing apple juice, etc.
- suspension dosage form of the present invention is bioequivalent to the immediate release marketed tablet of riociguat (Adempas® tablet).
- the suspension of the present invention provides advantages such as the absence of lumps even after long storage when the composition is shaken as well as good pourability.
- the suspension of the invention has good physical stability properties such as a low level of sedimentation (reduced or no caking) and easy re-dispersion on agitation. Moreover, it provides dose uniformity during each administration.
- the present inventors have observed that in the development of immediate release suspension dosage form of riociguat, the amount and ratio of drug, suspending agents, wetting agents and buffering agents are critical. Following are the key observations by the present inventors: a) for a successful immediate release suspension dosage form of riociguat, it is necessary to use the drug and suspending agent in specific ratio ranges i.e. from about 1:0.01 to 1:50. b) use the drug and wetting agent in a specific ratio range i.e. 1:2 or less, c) use the drug and buffering agents in specific ratio ranges i.e. 1: 10 or less.
- the drug and buffering agents is used in a specific ratio ranges from about 1 :0.01 to 1:5.
- the immediate release suspension dosage form of riociguat failed to achieve the desired assay and drug release and other technical attributes when ratios from about 1: 100 (drug and suspending agent); 1:3 (drug and wetting agent) and 1: 11 or more (drug and buffering agents) were used in test formulations.
- Carrier/vehicle/solvent used in the suspension of the present invention includes aqueous and non-aqueous carriers but are not limited to water, alcohol, polyethylene glycol, propylene glycol, glycerin, oil, or combinations thereof.
- Oils include peanut oil, soy bean oil, corn oil, sesame oil, cottonseed oil, acetylated glycerides, ethyl oleate, mineral oil, fatty acid esters, mono- or di- fatty acid esters of polyethylene glycols, or glyceryl mono-oleate.
- the suspensions are aqueousbased.
- aqueous carrier is meant a suspension comprising water, or a combination of water and a water-miscible organic solvent or solvents.
- Water-miscible solvents include but are not limited to propylene glycol, polyethylene glycol and ethanol.
- Non-aqueous carrier comprises a suspension in which the carrier does not include water.
- the carrier can also include one more pharmaceutically acceptable excipients which can be in dissolved or dispersed form.
- the carrier is present in an amount from about 5% to about 99%, particularly from about 40% to about 95% w/w or w/v.
- suspending agent enhances the physical stability of the composition by sufficiently increasing the viscosity so that an appropriate dose can be delivered with minimal shaking.
- Suitable suspending agents/viscosity agents are selected from the group comprising cellulose derivatives such as hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, methylcellulose, carboxymethyl cellulose and its salts/derivatives, e.g., carboxymethyl cellulose sodium, microcrystalline cellulose, and co-processed spray dried forms of microcrystalline cellulose and carboxymethyl cellulose sodium (such as Avicel® RC-501, Avicel® RC-581, Avicel® RC-591, and Avicel®CL-611); carbomers (available under the trade name Carbopol®); gums such as xanthan gum, locust bean gum, tragacanth gum, arabinogalactan gum, agar gum, gellan gum, guar gum, apricot gum, karaya gum, sterculia gum
- the suspending agents are present in an amount of about 0.05% to about 20% w/w or w/v of the composition. Particularly, the suspending agents are present in an amount of about 0.1% to about 10%, about 0.1% to about 5% and about 0.1% to about 3% w/w or w/v of the composition.
- the suspension is easily pourable and when shaken has a viscosity in the range of 100 cps (centipoise) to 10000 cps at 25°C.
- the viscosity is in the range of 100 cps to 5000 cps at 25°C, 100 cps to 2500 cps at 25°C, 100 cps to 1500 cps at 25°C, 300 cps to 4000 cps at 25°C. More particularly, the viscosity is in the range of 100 cps to 4000 cps at 25°C.
- shaken refers to shaken prior to use, e.g. by a patient, e.g. vigorously shaken, e.g. by hand, e.g. for 5 to 60 seconds.
- the viscosity can be measured by using a suitable instrument such as Brookfield viscometer, Haake VT 550 viscometer at room temperature (25°C).
- Suitable fillers or diluents include, but are not limited to sugars (e.g. sucrose, dextrose, fructose, lactose, maltose, invert sugar), sugar alcohols (e.g. sorbitol, mannitol, xylitol, lactitol, erythritol, maltodextrin, maltitol, isomaltitol, isomalt, maltulose, isomaltulose, lactulose, threitol, arabitol, ribitol, galactitol), starch, pregelatinized starch, calcium carbonate, calcium phosphate, dibasic anhydrous, calcium phosphate, dibasic dihydrate, calcium phosphate tribasic, calcium sulphate, cellulose powdered, silicified microcrystalline cellulose, cellulose acetate, magnesium carbonate, magnesium oxide, microcrystalline cellulose, polydextrose, sodium alginate, sodium
- sucrose has a particle size such that not less than 90% of particles are below 200 pm.
- sucrose has a particle size such that not less than 90% of particles are below 100 pm. This helps in achieving improved uniformity of the drug in the mixture.
- pH adjusting agent/ buffering agents include, but are not limited to, citrate buffers, phosphate buffers, or any other suitable buffer known in the art including monosodium dibasic phosphate, gluconic acid, lactic acid, citric acid, acetic acid, sodium gluconate, sodium lactate, sodium citrate, sodium acetate potassium citrate, sodium bicarbonate, potassium bicarbonate, sodium dihydrogen phosphate and potassium dihydrogen phosphate.
- the pH adjusting agents are present in an amount of about 0.1% to about 8% w/w or w/v of the composition.
- the amount of surfactant or wetting agent should be sufficient to facilitate the dispersion of riociguat in the suspension. At the same time, it should provide improved wettability of the riociguat.
- Suitable surfactant or wetting agents are selected from the group comprising non-ionic, anionic, cationic, or zwitterionic surfactants, and combinations thereof.
- surfactants are sodium lauryl sulphate; cetrimide; polyethylene glycols; polyglycerin fatty acid esters such as decaglyceryl monolaurate and decaglyceryl monomyristate; sorbitan fatty acid esters such as sorbitan monostearate; polyoxyethylene sorbitan fatty acid esters such as polyoxyethylene sorbitan monooleate; polysorbates (such as polysorbate 80); polyoxyethylene alkyl ether such as polyoxyethylene lauryl ether; polyoxyethylene castor oil; polyoxyethylene -polyoxypropylene block copolymers such as poloxamers (e.g.
- Poloxamer 188 polyoxyethylene stearate such as polyoxy 100 stearate (Myrj® 59P) as the wetting agent and combinations thereof.
- surfactant or wetting agents are non-ionic.
- the surfactant or wetting agents are present in an amount of about 0.01% to about 8% w/w or w/v of the composition.
- the surfactant or wetting agents are present in an amount of about 0.01% to about 3%, and more particularly from about 0.01% to about 1% w/w or w/v of the composition.
- Suitable preservatives include, but are not limited to, parabens such as methylparaben, propylparaben, butylparaben and their salts, sorbic acid, sodium sorbate, potassium sorbate, calcium sorbate, benzoic acid, sodium benzoate, potassium benzoate, calcium benzoate, methyl hydroxybenzoate, ethyl para-hydroxybenzoate, sodium ethyl para-hydroxybenzoate, sodium metabisulphite, chlorhexidine, diazolidinyl urea, sodium citrate, butylated hydroxyl toluene (BHT), butylated hydroxyl anisole (BHA), tocopherol, ethylenediamine tetraacetic acid, propyl gallate, quaternary compounds, e.g.
- the preservative is selected from benzoic acid and its salts and parabens.
- the preservative is present in an amount of about 0.001% to about 3% w/w or w/v of the composition.
- anticaking agents/glidants include, but are not limited to, colloidal silica and/or colloidal silicon dioxide (e.g. Aerosil® 200), magnesium trisilicate, calcium phosphate tribasic, magnesium oxide, magnesium silicate, calcium silicate, talc and combinations thereof.
- the anticaking agents are present in an amount of about 0.1% to about 10% w/w of the composition. More particularly, the anticaking agents are present in an amount of about 0.5% to about 7% w/w of the composition.
- antioxidants include, but are not limited to, ascorbic acid, tertbutylhydroquinone, sodium pyrosulfite, glutathione, sodium bisulfite, sodium sulfite, a-tocopherol, a-tocopherol acetate, monothioglycerol, cysteine, ascorbyl palmitate, acetylcysteine, dithiothreitol, sodium metabisulfite, thiourea, sodium thiosulfate, butylated hydroxyl anisole (BHA), butylated hydroxytoluene (BHT) and propyl gallate
- BHA butylated hydroxyl anisole
- BHT butylated hydroxytoluene
- the antioxidant is present in an amount from 0% to about 20%, from about 0.001% to about 5% w/w or w/v.
- Various useful sweetening agents include, but are not limited to, sugars such as sucrose, dextrose, fructose, lactose, maltose, invert sugar, sugar alcohols such as sorbitol, mannitol, xylitol, lactitol, erythritol, maltodextrin, maltitol, isomaltitol, isomalt, maltulose, isomaltulose, lactulose, threitol, arabitol, ribitol, galactitol, and sugar substitutes such as saccharin sodium, aspartame, acesulfame, and sucralose.
- sugars such as sucrose, dextrose, fructose, lactose, maltose, invert sugar
- sugar alcohols such as sorbitol, mannitol, xylitol, lactitol, erythritol, malto
- Sugar or a sugar alcohol can also act as a filler.
- the sweetening agents are present in an amount of 0% to about 90% w/w or w/v of the composition, particularly in an amount of about 0.1% to about 90% w/w or w/v of the composition, more particularly in an amount of about 0.1% to about 30% w/w or w/v of the composition.
- flavoring agents include, but are not limited to, flavors such as banana, lemon, orange, grape, lime and grapefruit, vanilla, bubble gum, peppermint, tutti-frutti, and fruit essence, including apple, banana, pear, peach, strawberry, raspberry, cherry, plum, pineapple, apricot; synthetic flavor oils and flavoring aromatics and/or natural oils, extracts from plant leaves, flowers, fruits such as cinnamon oil, oil of Wintergreen, peppermint oils, clove oil, citrus oil, bay oil, anise oil, eucalyptus, thyme oil, cedar leaf oil, oil of nutmeg, oil of sage, oil of bitter almonds, and cassia oil; maltol, ethyl vanillin, menthol, citric acid, fumaric acid, ethyl maltol, and tartaric acid and combinations thereof.
- the flavoring agents are present in an amount of about 0.1% to about 5% w/w or w/v of the composition.
- Various useful lubricants include, but are not limited to magnesium stearate, calcium stearate, stearic acid, and sodium stearyl fumarate.
- the lubricants are present in an amount of about 0.1% to about 5% w/w based on the total weight of the powder formulation.
- Suitable binders are selected from the group comprising gums such as guar gum, acacia, alginic acid, sodium alginate; carbomers; dextrin; maltodextrin; celluloses e.g., methylcellulose, ethyl cellulose, hydroxethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, hydroxyethylmethyl cellulose, carboxymethyl cellulose sodium; povidone; dextrose; polydextrose, starch, pregelatinized starch, microcrystalline cellulose, polymethacrylates including acrylic copolymers, gelatin, and mixture thereof.
- the binder is present in an amount of about 0.1% w/w to about 30% w/w of the composition.
- Suitable taste-masking agents include, but are not limited to, water soluble and/or insoluble polymeric excipient, water insoluble non-polymeric excipient, adsorbent, ion exchange resin, carbomer, alkali metal chlorides or an alkaline earth metal chlorides or a derivative thereof.
- Suitable antifoaming agents include, but are not limited to simethicone.
- Suitable coloring agents are selected from the group comprising FD&C (Federal Food, Drug and Cosmetic Act) approved coloring agents; natural coloring agents; natural juice concentrates; pigments such as iron oxide, titanium dioxide, and zinc oxide; and combinations thereof.
- FD&C Food, Drug and Cosmetic Act
- the pharmaceutical composition of the present invention can be packaged in a suitable pack/container such as amber-colored polyethylene terephthalate (PET) bottle, glass bottle, vials, high density polyethylene (HDPE) bottle, low density polyethylene (LDPE) bottle, polypropylene (PP) bottle, packets, pouches, sachets and the like.
- a suitable pack/container such as amber-colored polyethylene terephthalate (PET) bottle, glass bottle, vials, high density polyethylene (HDPE) bottle, low density polyethylene (LDPE) bottle, polypropylene (PP) bottle, packets, pouches, sachets and the like.
- the glass or plastic bottle is provided with a child proof closure.
- the package can include a syringe (marked in mL) for ease of dosing.
- the suspension powder formulation can be for a single dose or multiple doses after reconstitution with a carrier.
- the container such as bottle has a fill volume of, e.g., from about 20 mL to about 300 mL comprising riociguat suspension.
- Pack chosen are made of material which is non-reactive with the suspension and suspension powder for reconstitution.
- Containers for use in the storage of the oral suspensions may be used to administer a multiple dose of riociguat.
- the suspension powder for reconstitution can be provided in a kit comprising (a) suspension powder for reconstitution of riociguat and (b) a pharmaceutically acceptable carrier.
- a suspension comprising riociguat
- the suspension is provided in a kit comprising: (a) an immediate release oral pharmaceutical ready to use suspension comprising riociguat, and (b) a dosing syringe for administering the suspension.
- the suspensions of the present invention are homogenous and deliver the desired dose of riociguat in every use without any risk of overdosing or underdosing.
- the compositions provide predictable riociguat release throughout the shelf life. pH Measurement: pH values are determined using potentiometry using USP ⁇ 791>.
- Viscosity Measurement The viscosity can be measured by using a suitable instrument such as Brookfield viscometer, Haake VT 550 viscometer at room temperature (25°C).
- the powder for suspension was evaluated for in-vitro riociguat release.
- the in-vitro dissolution is determined using a USP type II apparatus at 75 rpm in 900 mL of pH 6.8 phosphate buffer with 0.1% sodium lauryl sulfate at 37 ⁇ 0.5°C by HPLC method.
- Example 6-11 Suspension powder for reconstitution of riociguat
- the suspension powder for reconstitution is reconstituted with a suitable carrier such as water when required.
- a suitable carrier such as water when required.
- Example 12-15 Ready-To-Use Suspension of riociguat
- Suitable sweetener/diluent was added to the purified water and was stirred to get a clear solution.
- Suitable suspending agent was added to the solution and was stirred for a suitable time (30 minutes).
- a suitable buffer solution was prepared by adding pH-adjusting agents in purified water and was added to the dispersion.
- Suitable wetting agents and riociguat were added in the dispersion and were stirred for a suitable time period.
- Suitable preservatives methylparaben and propylparaben
- a suitable carrier such as glycerin (heated at 80°C) and were cooled at room temperature and were added to the suspension (example 13-14) or sodium benzoate was added in to the suspension (example 15).
- Suitable sweetening and flavoring agents were added to the suspension and were stirred for a suitable time. Suspension was homogenized for a suitable time period. Volume of suspension was adjusted with a suitable liquid carrier and was stirred the final suspension for a suitable time (30 minutes). The suspension was filled into a suitable container closure system.
- results The dissolution, pH and assay of dosage forms prepared using quantitative formula is given below.
- the dissolution profile was measured in 900 ml of 6.8 phosphate buffer and 0.1% sodium lauryl sulfate (SLS) using a USP II apparatus (Paddle) at a temperature of 37 ⁇ 0.5°C and a rotation speed of 75 revolutions per minute.
- SLS sodium lauryl sulfate
- the test examples exhibited desired pharmaceutical formulation technical attributes such as dissolution profile, pH, and assay.
- Test formulations pH was determined in the range of 3-7.
Abstract
The present invention relates to orally administered immediate release pharmaceutical suspensions of riociguat. The immediate release suspensions are in the form of ready to use suspension. It also relates to the processes for the preparation of said suspensions. The present invention provides suspensions of riociguat which are expected to exhibit desired technical attributes such as viscosity, pH, dissolution, assay and stability. The prepared compositions are useful in patients having difficulties in swallowing tablets and provide enhanced patient compliance over conventional tablet dosage form.
Description
PHARMACEUTICAL ORAL SUSPENSIONS OF RIOCIGUAT
FIELD OF THE INVENTION
The present invention relates to orally administered, pharmaceutical immediate release suspensions of riociguat. The immediate release suspensions are in the form of ready to use suspension and suspension powder for reconstitution. It also relates to the processes for the preparation of said suspensions. It further relates to the use of pharmaceutical suspensions for the treatment of hypertension and related disorders.
BACKGROUND OF THE INVENTION
Riociguat is an antihypertensive drug. It is chemically known as methyl 4,6-diamino-2-[l-(2- fluorobenzyl)-lH-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl(methyl)carbamate and is represented by the following formula as:
Riociguat is marketed in the USA as an immediate release tablet in 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg strengths under the brand name Adempas® by Bayer Healthcare Pharmaceuticals. The marketed solid dosage form of riociguat is indicated for the treatment of persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) to improve exercise capacity.
U.S. Patent No. 7,173,037, assigned to Bayer Healthcare, discloses riociguat as a new compound. This patent also discloses the use of riociguat in the treatment of hypertension.
U.S. Patent No. 10,087,183, assigned to Bayer Healthcare, discloses polymorphs of riociguat such as modification I, modification II, mono-DMSO solvate, sesqui-DMSO solvate, l^-ethyl acetate solvate and pharmaceutical composition thereof. The publication highlights various polymorphic forms of riocugat and the conversion of these polymorphs into other forms.
U.S. Patent No. 9,884,859, assigned to Sunshine Lake Pharma, discloses crystalline form III and form IV of riociguat.
U.S. Patent No. 10,414,766, assigned to Alembic Pharmaceuticals, discloses crystalline form AL of riociguat.
Difficulty in swallowing tablets and capsules is a problem for many patients and can induce significant non-compliance with the prescribed treatment regimens. Adolescents, children, and the elderly are particularly vulnerable population groups that are more likely than adults to experience difficulty in swallowing tablets or capsules.
The prescribing information of Adempas® tablet mentions that the riociguat tablets may be crushed and mixed with water or soft foods for patients who have difficulty in swallowing. However, an extemporaneously created dispersion of riociguat is physicochemically not stable leading to highly variable riociguat dosing with accompanying unpredictable therapeutic efficacy.
Till date, no suspension formulation of riociguat is commercially available. There is an unmet need in the art to provide immediate release suspension dosage forms of riociguat which are stable, no conversion into undesirable polymorphs, provide ease of administration, ease of dose adjustment, and enhanced patient compliance.
The inventors of the present invention have developed a suspension dosage form of riociguat with an objective to minimize swallowing difficulties, which is likely to improve patient compliance by reducing dysphagia-related adverse events and accordingly providing a more convenient and less cumbersome posology. The inventors have developed immediate release, ready to use suspension and/or suspension powder for reconstitution convenient for administration to paediatric and geriatric patients, easy to manufacture, functionally reproducible, and provides ease of dose adjustment. Further, the suspension dosage form exhibits desirable technical attributes such as pourability, viscosity, pH, dissolution, re-suspendability, assay and chemical and physical stability.
SUMMARY OF THE INVENTION
It is a principal object of the present invention to provide a stable immediate release oral pharmaceutical suspension dosage form of riociguat comprising riociguat and at least one or more pharmaceutically acceptable excipients and a process for its preparation. The suspension dosage form of the present invention is in the form of immediate release ready to use suspension and/or immediate release suspension powder for reconstitution.
It is another object of the present invention to provide an immediate release oral pharmaceutical suspension dosage form of riociguat comprising riociguat and at least one or more pharmaceutically acceptable excipients; wherein the one or more pharmaceutically acceptable excipients are selected from the group comprising of suspending agent, buffer/pH adjusting agent, diluent, carrier, antioxidant, anticaking agent, antifoaming agent, coloring agent, sweetening agent, flavoring agent, surfactant/solubilizer/wetting agent, preservative, glidant, binder, and mixtures thereof.
It is another object of the present invention to provide an immediate release, ready to use suspension comprising riociguat and at least one or more pharmaceutically acceptable excipients and a process for its preparation.
It is another object of the present invention to provide an immediate release suspension powder for reconstitution comprising riociguat and at least one or more pharmaceutically acceptable excipients and a process for its preparation.
It is another object of the present invention to provide an immediate release suspension dosage form comprising riociguat in an amount of about 0.01% to about 30% by weight, wherein the suspension dosage form exhibits desirable technical attributes like pourability, viscosity, dissolution, stability (physical, chemical and polymorph stability), re-suspendability and a process for preparing the same.
In accordance with still another embodiment of the present invention, there is provided an immediate release suspension dosage form comprising riociguat for use in the treatment of hypertension, pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension, persistent/recurrent chronic thromboembolic pulmonary hypertension, heart failure, arrhythmia, high blood pressure, angina pectoris, myocardial infarction, stroke, transient ischaemic attacks, arteriosclerosis, erectile dysfunction, osteoporosis, Alzheimer's disease, Parkinson's disease, multiple sclerosis, depression, schizophrenia, bipolar disorder and migraine.
DETAILED DESCRIPTION OF THE INVENTION
The present invention can be more readily understood by following detailed description of the invention and study of the included examples.
As used herein, the term “composition or “formulation” or “dosage form”, as in pharmaceutical composition, is intended to encompass a drug product comprising riociguat or its pharmaceutically acceptable salts, esters, solvates, polymorphs, enantiomers or mixtures thereof, and
other inert ingredient(s) (pharmaceutically acceptable excipients). Such pharmaceutical compositions are synonymous with “formulation” and “dosage form”. Pharmaceutical composition of the invention includes, but is not limited to immediate release ready to use suspension, powder for suspension, granules for suspension, pellets, beads, multiparticulates, and the like. Particularly, the pharmaceutical composition refers to powder, granules, pellets, beads, multiparticulates, and the like filled into capsules or sachets, and ready to use suspension.
As used herein, the term “ready to use suspension” means a pre-constituted suspension which can be administered as such to patient. The “powder for suspension” or “suspension powder for reconstitution” or “dry suspension” or “granules for suspension” are synonymous and are reconstituted with a liquid carrier like water to form a suspension.
As used herein, the term “riociguaf ’ is used in broad sense to include not only “riociguaf ’ per se but also its pharmaceutically acceptable salts, solvates, hydrates, enantiomers, derivatives, isomers, polymorphs, stereoisomers, diastereoisomers prodrugs thereof, and also its various crystalline and amorphous forms or mixtures thereof. Riociguat is present in an amount from about 0.01% to about 70% of the suspension dosage form, particularly from about 0.01% to about 30%, from about 0.01% to about 20%, from about 0.01% to about 10%, from about 0.01% to about 5%, from about 0.01% to about 3% w/w or w/v of the suspension dosage form.
The term “excipient” means a pharmacologically inactive component such as a suspending agent, pH adjusting agent/buffering agent, diluent, carrier, anticaking agent, antifoaming agent, antioxidant, sweetening agent, flavoring agent, surfactant/solubilizer/wetting agent, buffer, glidant, binder, preservative, and the like. Reference to an excipient includes both one and more than one such excipient. Co-processed excipients are also covered under the scope of present invention. Combination of excipients performing the same function may also be used to achieve desired formulation characteristics.
The term “immediate release,” as used herein, implies that riociguat is released from the composition in an immediate release fashion. Immediate release refers to pharmaceutical compositions that release at least 75% of the active ingredient within a small period of time, typically less than 60 minutes and more particularly in less than 45 minutes and most particularly more than 85% of drug release within 30 minutes.
As used herein, the term “about” means ± approximately 10% of the indicated value, such that “about 10 percent” indicates approximately 08 to 12 percent.
As used in this specification, the singular forms “a”, “an”, and “the” include plural references unless the context clearly dictates otherwise. Thus, for example, a reference to “a process” includes one or more process, and/or steps of the type described herein and/or which will become apparent to those persons skilled in the art upon reading this disclosure and so forth.
The term “stable,” as used herein, refers to chemical stability, wherein not more than 5% w/w of total related substances are formed on storage at 40°C and 75% relative humidity (R.H.) or at 25 °C and 60% R.H. for a period of at least 1 week, for a period of at least one month, particularly for a period of two months, and more particularly for a period of at least three months.
Unless otherwise stated the weight percentages expressed herein are based on the final weight or volume of the composition or formulation.
The following embodiments further describe the objects of the present invention in accordance with the best mode of practice, however, disclosed invention is not restricted to the particular embodiments hereinafter described.
In accordance with one embodiment of the present invention, there is provided a stable immediate release oral pharmaceutical suspension dosage form of riociguat comprising riociguat and at least one or more pharmaceutically acceptable excipients.
In accordance with another embodiment of the present invention, the immediate release oral pharmaceutical suspension dosage form of riociguat is a ready-to-use suspension and suspension powder for reconstitution.
In accordance with another embodiment of the present invention, there is provided an immediate release oral pharmaceutical suspension dosage form of riociguat comprising: a) riociguat; b) a suspending agent; and c) at least one or more pharmaceutically acceptable excipients.
In accordance with another embodiment of the present invention, there is provided an immediate release oral pharmaceutical suspension dosage form of riociguat comprising: a) riociguat from about 0.01% to about 30% w/w; b) a suspending agent from about 0.05% to about 20% w/w; and c) at least one or more pharmaceutically acceptable excipients.
In accordance with another embodiment of the present invention, there is provided an immediate release oral pharmaceutical suspension dosage form of riociguat comprising:
a) riociguat from about 0.01% to about 30% w/w; b) a suspending agent from about 0.05% to about 20% w/w; and c) at least one or more pharmaceutically acceptable excipients; wherein the pH of the suspension is from about 3 to about 8.
In accordance with another embodiment of the present invention, there is provided an immediate release ready to use oral pharmaceutical suspension of riociguat comprising: a) riociguat from about 0.01% to about 30% w/w; b) a suspending agent from about 0.05% to about 20% w/w; and c) a pharmaceutically acceptable liquid carrier.
In accordance with another embodiment of the present invention, there is provided an immediate release oral pharmaceutical suspension powder for reconstitution of riociguat comprising: a) riociguat from about 0.01% to about 30% w/w; b) a suspending agent from about 0.05% to about 20% w/w; and c) one or more pharmaceutically acceptable excipients.
In accordance with another embodiment of the present invention, there is provided an immediate release oral pharmaceutical suspension dosage form of riociguat comprising: a) riociguat; b) a suspending agent; and c) at least one or more pharmaceutically acceptable excipients; wherein the dosage form exhibits an in-vitro dissolution rate of more than 50% of drug release within 30 minutes when the said dosage form is placed in a dissolution vessel filled with 900 ml of pH 6.8 phosphate buffer with 0.1% sodium lauryl sulfate (SLS) maintained at 37±0.5°C and stirred at a paddle speed of 75 rpm using a USP Type II (paddle) apparatus.
In accordance with another embodiment of the present invention, there is provided an immediate release oral pharmaceutical suspension powder for reconstitution of riociguat comprising riociguat and a suspending agent, wherein the suspending agent is present in an amount ranging from about 0.05% to about 20% w/w in the powder formulation.
In accordance with another embodiment of the present invention, there is provided an immediate release oral pharmaceutical suspension dosage form of riociguat comprising riociguat and a suspending agent, wherein the riociguat and suspending agent have a ratio ranging from about 1 :
0.01 to 1:40 by weight. In a preferred embodiment, the riociguat and suspending agent have a ratio ranging from about 1:0.01 to 1:50. In a preferred embodiment, the riociguat and suspending agent have a ratio ranging from about 1 : 10 to 1 :50. In a preferred embodiment, the riociguat and suspending agent have a ratio ranging from about 1:0.01 to 1:25. In a preferred embodiment, the riociguat and suspending agent have a ratio of about 1:25. In a preferred embodiment, the riociguat and suspending agent have a ratio of about 1:22.5. In a preferred embodiment, the riociguat and suspending agent have a ratio of about 1 : 10. In a preferred embodiment, the riociguat and suspending agent have a ratio of about 1:5.
In accordance with another embodiment of the present invention, there is provided an immediate release oral pharmaceutical suspension dosage form of riociguat comprising riociguat and wetting agent, wherein the riociguat and wetting agent have a ratio ranging from about 1 :0.01 to 1 : 10, preferably, ranging from about 1:0.01 to 1:5.
In accordance with another embodiment of the present invention, the immediate release oral pharmaceutical suspension dosage form of riociguat is a ready-to-use suspension and suspension powder for reconstitution.
In accordance with another embodiment of the present invention, the immediate release oral pharmaceutical suspension dosage form of riociguat, wherein riociguat is present in an amount from about 0.05 mg/mL to about 30 mg/mL and viscosity from about 100 cps to about 4000 cps. In a preferred embodiment, the viscosity of the suspension is from about 100 cps to about 3000 cps. In a preferred embodiment, the viscosity of the suspension is from about 100 cps to about 1000 cps. In a preferred embodiment, the amount of riociguat in the suspension ranges from about 0.05 mg/mL to about 7.5 mg/mL. In a preferred embodiment, the amount of riociguat in the suspension ranges from about 0.05 mg/mL to about 5 mg/mL.
In accordance with another embodiment of the present invention, there is provided an immediate release oral pharmaceutical suspension dosage form of riociguat comprising: a) riociguat or its pharmaceutically acceptable salt, ester, hydrate or polymorph thereof; b) a suspending agent; c) a pH adjusting agent; and d) one or more pharmaceutically acceptable excipients.
In accordance with another embodiment of the present invention, there is provided an immediate release oral pharmaceutical suspension dosage form of riociguat comprising:
a) riociguat or its pharmaceutically acceptable salt, ester, hydrate or polymorph thereof; b) a suspending agent; c) pH adjusting agent to maintain the pH of the composition in the range of about 3 to about 8; d) optionally a surfactant; e) optionally a preservative; and f) one or more pharmaceutically acceptable excipients.
In accordance with another embodiment of the present invention, there is provided an immediate release oral pharmaceutical suspension dosage form of riociguat comprising: a) riociguat or its pharmaceutically acceptable salt, ester, hydrate or polymorph thereof; b) a suspending agent; c) a pH adjusting agent to maintain the pH of the composition in the range of about 3 to about 8; and d) a diluent or a pharmaceutically acceptable liquid carrier.
In accordance with another embodiment of the present invention, there is provided an immediate release oral pharmaceutical suspension dosage form of riociguat comprising: a) riociguat; b) a suspending agent; c) optionally a pH adjusting agent; and d) one or more pharmaceutically acceptable excipients; wherein the suspending agent is selected from the group comprising of xanthan gum, gellan gum, cellulose and its derivatives, a mixture of carboxymethylcellulose and microcrystalline cellulose, propylene glycol alginate, and combinations thereof.
In accordance with another embodiment of the present invention, there is provided an immediate release oral pharmaceutical suspension dosage form of riociguat comprising: a) riociguat or its pharmaceutically acceptable salt, ester, hydrate or polymorph thereof a) a suspending agent; b) a surfactant; c) optionally a preservative; d) optionally an antioxidant;
e) pH adjusting agent in sufficient amounts to maintain the pH of the composition in the range of about 3 to about 8; and f) a diluent or a pharmaceutically acceptable liquid carrier.
In accordance with another embodiment of the present invention, there is provided an immediate release oral pharmaceutical suspension dosage form of riociguat or its pharmaceutically acceptable salt, ester, hydrate or polymorph thereof with one or more pharmaceutically acceptable excipients comprising riociguat from about 0.05 mg/mL to about 30 mg/mL, wherein the pH of the composition is from about 3 to about 8.
In accordance with another embodiment of the present invention, there is provided an immediate release oral pharmaceutical suspension dosage form comprising: a) riociguat in an amount of about 0.01 % to about 30% w/v of the dosage form; b) a suspending agent selected from xanthan gum, mixture of microcrystalline cellulose and sodium carboxymethyl cellulose, propylene glycol alginate, and gellan gum in an amount from about 0.05% to about 20% w/v of the dosage form; c) a wetting agent selected from poloxamer, polysorbate, polyoxyethylene stearate and combination thereof in an amount from about 0.01% to about 5% w/v of the dosage form; d) pH adjusting agent or buffering agent selected from citric acid, trisodium citrate, citrate buffer, monosodium dibasic phosphate, tribasic sodium phosphate and combination thereof in an amount from about 0.01% to about 5% w/v of the dosage form; e) a pharmaceutically acceptable liquid carrier selected from water, glycerin, propylene glycol, aqueous sorbitol solution, aqueous buffer solution and combination thereof in an amount from about 10% to about 95% w/v of the dosage form; and f) at least one or more other pharmaceutically acceptable excipients; wherein the pH of the suspension is from 3 to 7. Preferably, the pH of the suspension is from 4 to 6. In another embodiment, riociguat has a particle size distribution D90 less than about 20 pm, preferably 10 pm and more preferably 6.7 pm.
In accordance with another embodiment of the present invention, there is provided an immediate release oral pharmaceutical suspension dosage form comprising: a) riociguat in an amount of about 0.01% to about 5% w/v of the dosage form; b) a suspending agent selected from xanthan gum, mixture of microcrystalline cellulose and
sodium carboxymethyl cellulose, propylene glycol alginate, and gellan gum in an amount from about 0.05% to about 3% w/v of the dosage form; c) a wetting agent selected from poloxamer, polysorbate, polyoxyethylene stearate and combination thereof in an amount from about 0.01% to about 2% w/v of the dosage form; d) liquid carrier selected from water, glycerin and combination thereof in an amount from about 10% to about 95% w/v of the dosage form; and e) at least one or more other pharmaceutically acceptable excipients; wherein the pH of the suspension is from 3 to 6 and suspension exhibits an in-vitro dissolution rate of more than 85% of drug release within 30 minutes when measured in 900 ml of 6.8 phosphate buffer and 0.1% sodium lauryl sulfate using a USP II apparatus (Paddle) at a temperature of 37±0.5°C and a rotation speed of 75 revolutions.
In accordance with another embodiment of the present invention, there is provided an immediate release oral pharmaceutical suspension dosage form comprising: a) riociguat in an amount of about 0.01% to about 5% w/v of the dosage form; b) a suspending agent selected from xanthan gum, mixture of microcrystalline cellulose and sodium carboxymethyl cellulose, propylene glycol alginate, and gellan gum in an amount from about 0.05% to about 3% w/v of the dosage form; c) a wetting agent selected from poloxamer, polysorbate, polyoxyethylene stearate and combination thereof in an amount from about 0.01% to about 2% w/v of the dosage form; d) citric acid in an amount from about 0.01% to about 2% w/v of the dosage form; e) trisodium citrate in an amount from about 0.01% to about 2% w/v of the dosage form; f) sorbitol in an amount from about 0.01% to about 11% w/v of the dosage form; g) methylparaben and propylparaben in an amount from about 0.01% to about 1% w/v of the dosage form; and h) liquid carrier selected from water, glycerin and combination thereof in an amount from about 10% to about 95% w/v of the dosage form; wherein the pH of the suspension is from 3 to 6 and the riociguat and suspending agent have a ratio ranging from about 1:0.01 to 1:25.
In accordance with another embodiment of the present invention, there is provided an immediate release oral pharmaceutical suspension dosage form comprising:
a) riociguat in an amount of about 0.01% to about 5% w/v of the dosage form, b) xanthan gum in an amount from about 0.05% to about 3% w/v of the dosage form; c) polysorbate 80 in an amount from about 0.01 % to about 2% w/v of the dosage form; d) citric acid in an amount from about 0.01 % to about 2% w/v of the dosage form, e) trisodium citrate in an amount from about 0.01% to about 2% w/v of the dosage form; f) sorbitol in an amount from about 0.01% to about 11% w/v of the dosage form; g) sodium benzoate in an amount from about 0.01% to about 1% w/v of the dosage form; h) thaumatin in an amount from about 0.01% to about 2% w/v of the dosage form; i) liquid carrier selected from water, glycerin and combination thereof in an amount from about 10% to about 95% w/v of the dosage form; wherein the pH of the suspension is from 3 to 8.
In accordance with another embodiment of the present invention, there is provided an immediate release oral pharmaceutical suspension dosage form comprising: a) riociguat in an amount of about 0.05 mg/mL to about 7.5 mg/mL of the dosage form; b) a suspending agent selected from xanthan gum, mixture of microcrystalline cellulose and sodium carboxymethyl cellulose, propylene glycol alginate, and gellan gum in an amount from about 0.1 mg/ml to about 10 mg/ml of the dosage form; c) a wetting agent selected from poloxamer, polysorbate, polyoxyethylene stearate and combination thereof in an amount about 0.01 mg/ml to about 5 mg/ml of the dosage form; d) pH adjusting agent or buffering agent selected from citric acid, trisodium citrate, citrate buffer, monosodium dibasic phosphate, tribasic sodium phosphate and combination thereof in an amount from about 0.01 mg/ml to about 5 mg/ml of the dosage form; and e) a pharmaceutically acceptable liquid carrier selected from water, glycerin and combination thereof in an amount up to 1ml for 1ml suspension dosage form; wherein the pH of the suspension is from 3 to 6 and wherein riociguat has a particle size distribution D90 less than about 20 pm.
In accordance with another embodiment of the present invention, there is provided an immediate release oral pharmaceutical suspension dosage form which exhibits an in-vitro dissolution rate of
more than 85% of drug release within 30 minutes, when measured in 900 ml of 6.8 phosphate buffer and 0.1% sodium lauryl sulfate (SLS) using a USP II apparatus (Paddle) at a temperature of 37±0.5°C and a rotation speed of 75 revolutions
In accordance with another embodiment of the present invention, there is provided an immediate release oral pharmaceutical suspension dosage form comprises one or more sweetening agents selected from the group consisting of sucrose, dextrose, sucralose, sorbitol, fructose, mannitol, saccharin sodium, aspartame, thaumatin and combination thereof in an amount of about 0.1% w/w to about 20% w/w or w/v of the dosage form.
In accordance with another embodiment of the present invention, there is provided an immediate release oral pharmaceutical suspension dosage form comprises one or more preservatives selected from the group consisting of parabens such as methylparaben, propylparaben, butylparaben benzoic acid, sodium benzoate, potassium benzoate, butylated hydroxyl toluene, butylated hydroxyl anisole, tocopherol, benzalkonium chloride and combination thereof in an amount of about 0.001% w/w to about 3% w/w or w/v of the dosage form.
In accordance with another embodiment of the present invention, there is provided an immediate release oral pharmaceutical suspension dosage form comprises one or more flavoring agents selected from the group consisting of orange, grape, lime, vanilla, bubble gum, peppermint, tutti-frutti, strawberry, and combination thereof in an amount of about 0.01% w/w to about 5% w/w of the dosage form. Preferably, the dosage form comprises one or more flavoring agents in an amount from about 0.01% to about 1% w/w or w/v of the dosage form.
In accordance with another embodiment of the present invention, there is provided an immediate release oral pharmaceutical suspension dosage form of riociguat comprising riociguat from about 0.05 mg/mL to about 30 mg/mL, wherein the pH of the composition is from about 3 to about 8 and viscosity from about 100 cps to about 4000 cps.
In a preferred embodiment, there is provided an immediate release oral pharmaceutical suspension dosage form of riociguat comprising riociguat about lmg/5 mL. In a preferred embodiment, there is provided an immediate release oral pharmaceutical suspension dosage form of riociguat comprising riociguat about 1 mg/mL.
In accordance with still another embodiment of the present invention, there is provided an immediate release oral pharmaceutical suspension dosage form of riociguat, wherein the composition is free from other polymorphic forms.
In accordance with another embodiment of the present invention, there is provided a suspension powder for reconstitution of riociguat comprising riociguat and at least one or more pharmaceutically acceptable excipients selected from the group comprising a suspending agent, pH adjusting agent/buffer, antioxidant, anticaking agent, antifoaming agent, coloring agent, sweetening agent, flavouring agent, surfactant/wetting agent, diluent, carrier, glidant, binder, and preservative.
In accordance with another embodiment of the present invention, there is provided a ready to use suspension of riociguat comprising riociguat, a pharmaceutically acceptable carrier and at least one or more pharmaceutically acceptable excipients selected from the group comprising of: suspending agent, antioxidant, anticaking agent, antifoaming agent, pH adjusting agent/buffer, coloring agent, sweetening agent, flavouring agent, surfactant/wetting agent, diluent, glidant, binder, and preservative.
In accordance with another embodiment of the present invention, there is provided a dry powder for suspension compositions of riociguat suitable for use as a liquid suspension for children or elderly patients.
In accordance with still another embodiment of the present invention, there is provided a process for the preparation of an immediate release oral pharmaceutical suspension dosage form of riociguat comprising riociguat in micronized form.
In accordance with one embodiment of the present invention, there is provided an immediate release oral pharmaceutical suspension dosage form of riociguat which is stable.
In accordance with still another embodiment of the present invention, there is provided a process for the preparation of a ready to use suspension of riociguat comprising combining various components using conventional equipment such as overhead stirrers, ultrasonifiers, mills, homogenizers. Many different orders of addition of components can be employed.
In accordance with still another embodiment of the present invention, there is provided a process for the preparation of a suspension powder for reconstitution of riociguat comprising admixing riociguat granules with at least one or more pharmaceutically acceptable excipients selected from the group comprising of suspending agent, pH adjusting agent/buffer, diluent, carrier, antioxidant, anticaking agent, antifoaming agent, coloring agent, sweetening agent, flavoring agent,
surfactant/solubilizer/wetting agent, preservative, glidant, binder, disintegrant, antioxidant, and mixtures thereof to form a dry admixture, and transferring the dry admixture to a sealable storage container.
In accordance with still another embodiment of the present invention, there is provided a pharmaceutical suspension dosage form of riociguat, wherein riociguat has a particle size distribution D90 less than about 200 pm, D50 is less than about 100 pm and Dio is less than about 50 pm. D90 of riociguat ranges about 0.1 pm to 200 pm, particularly from 1 pm to 150 pm, 1 pm to 100 pm, from about 1 pm to about 75 pm, particularly from about 1 pm to about 50 pm, particularly from about 1 pm to about 30 pm, particularly from about 1 pm to about 20 pm, more particularly from 1 pm to about 10 pm, and more particularly from 1 pm to about 6.7 pm. D50 ranges from about 1 pm to about 100 pm. The particle size of riociguat can be measured by suitable techniques such as Laser light scattering (e.g. Malvern Light Scattering), Coulter counter, microscopy and any other technique known in the art.
In accordance with another embodiment of the present invention, there is provided an immediate release pharmaceutical suspension dosage form comprising riociguat for use in the treatment of hypertension, persistent/recurrent chronic thromboembolic pulmonary hypertension, pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension, heart failure, arrhythmia, high blood pressure, angina pectoris, myocardial infarction, stroke, transient ischaemic attacks, arteriosclerosis, erectile dysfunction, osteoporosis, Alzheimer's disease, Parkinson's disease, multiple sclerosis, depression, schizophrenia, bipolar disorder and migraine.
In accordance with another embodiment of the present invention, there is provided a method of treating hypertension, persistent/recurrent chronic thromboembolic pulmonary hypertension, pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension, heart failure, arrhythmia, high blood pressure, angina pectoris, myocardial infarction, stroke, transient ischaemic attacks, arteriosclerosis, erectile dysfunction, osteoporosis, Alzheimer's disease, Parkinson's disease, multiple sclerosis, depression, schizophrenia, bipolar disorder and migraine by administering an immediate release oral pharmaceutical suspension dosage form of riociguat of the present invention.
In accordance with another embodiment of the present invention, there is provided an immediate release oral pharmaceutical suspension dosage form of riociguat, wherein the pH of the suspension is in the range of about 3-9. Preferably, the pH is in a range of about 3 to about 8. More
preferably, the pH is in a range of about 3 to about 6. More preferably, the pH is in a range of about 3 to about 5.5.
In accordance with another embodiment of the present invention, there is provided an immediate release oral pharmaceutical suspension dosage form of riociguat, wherein the suspension dosage form comprises less than 2% of total impurities, preferably less than 1% of total impurities. In another embodiment, the dosage form comprises less than 0.5% of carbamate impurity. In another embodiment, the dosage form comprises less than 0.5% of des-fluoro impurity. In another embodiment, the dosage form comprises less than 0.5% of dimethyl impurity. In another embodiment, the dosage form comprises less than 0.5% of methyl isopropyl impurity. In another embodiment, the immediate release pharmaceutical suspension dosage form comprises less than 2% of total impurities and less than 0.5% of carbamate impurity.
In accordance with other embodiment, riociguat is the sole active ingredient in the suspension dosage form.
In accordance with other embodiment, the suspension dosage form of riociguat of the present invention is sugar free.
In accordance with other embodiment, the suspension dosage form of riociguat is microbiologically stable.
In accordance with other embodiment of the present invention, there is provided an immediate release suspension dosage form comprising riociguat, wherein the suspension is a ready to use suspension packaged in a bottle.
In accordance with yet another embodiment of the present invention, there is provided an immediate release suspension dosage form comprising riociguat, wherein the suspension is a powder for suspension packaged in a bottle or a sachet.
In accordance with one embodiment of the present invention, there is provided a process for the preparation of a suspension dosage form comprising riociguat, wherein the process utilized is mixing, blending, dry granulation, wet granulation, hot-melt extrusion process, extrusion spheronization, fluidized bed granulation, dispersion, homogenization or the like.
In accordance with one embodiment of the present invention, there is provided a process for preparation of a ready to use suspension of riociguat, wherein the process comprises the following steps:
(i) dissolving/dispersing one or more pharmaceutically acceptable excipients in a portion of water;
(ii) dispersing riociguat in the mixture of step (i) to form a dispersion;
(iii) mixing suspending agent in another portion of water;
(iv) adding the mixture of step (iii) to the dispersion of step (ii); and
(v) optionally adding one or more pharmaceutically acceptable excipients to the dispersion of step (iv); and
(vi) optionally homogenizing the mixture of step (iv) to form a suspension.
In accordance with other embodiment of the present invention, there is provided a process for preparation of a suspension powder for reconstitution of riociguat wherein process comprises the following steps:
(i) mixing riociguat with one or more pharmaceutically acceptable excipients;
(ii) granulating the mixture of step (i) using a solvent;
(iii) drying the granulated mixture of step (ii);
(iv) milling the mixture of step (iii) to form granules; and
(v) mixing the granules of step (iv) optionally with one or pharmaceutically acceptable excipients to form the suspension powder for reconstitution.
In accordance with other embodiment of the present invention, there is provided a process for preparation of a suspension powder for reconstitution of riociguat, wherein the process comprises the following steps:
(i) mixing riociguat with one or more pharmaceutically acceptable excipients;
(ii) compacting the mixture of step (i) to form slugs;
(iii) milling the slugs of step (ii) to form granules; and
(iv) mixing the granules of step (iii) optionally with one or pharmaceutically acceptable excipients to form the suspension powder for reconstitution.
In accordance with other embodiment of the present invention, there is provided a process for preparation of a suspension powder for reconstitution of riociguat, wherein the process comprises the following steps:
(i) mixing riociguat with one or more pharmaceutically acceptable excipients; and
(ii) optionally lubricating the mixture of step (i) to form the suspension powder for reconstitution.
Powder/granules for oral suspension can be reconstituted using water or powder/granules for oral suspension can be administered by sprinkling the powder/granules on soft food like yoghurt, applesauce or empty granules into a small cup or teaspoon containing apple juice, etc.
In yet another embodiment, the suspension dosage form of the present invention is bioequivalent to the immediate release marketed tablet of riociguat (Adempas® tablet).
The suspension of the present invention provides advantages such as the absence of lumps even after long storage when the composition is shaken as well as good pourability. The suspension of the invention has good physical stability properties such as a low level of sedimentation (reduced or no caking) and easy re-dispersion on agitation. Moreover, it provides dose uniformity during each administration.
The present inventors have observed that in the development of immediate release suspension dosage form of riociguat, the amount and ratio of drug, suspending agents, wetting agents and buffering agents are critical. Following are the key observations by the present inventors: a) for a successful immediate release suspension dosage form of riociguat, it is necessary to use the drug and suspending agent in specific ratio ranges i.e. from about 1:0.01 to 1:50. b) use the drug and wetting agent in a specific ratio range i.e. 1:2 or less, c) use the drug and buffering agents in specific ratio ranges i.e. 1: 10 or less. Preferably, the drug and buffering agents is used in a specific ratio ranges from about 1 :0.01 to 1:5. The immediate release suspension dosage form of riociguat failed to achieve the desired assay and drug release and other technical attributes when ratios from about 1: 100 (drug and suspending agent); 1:3 (drug and wetting agent) and 1: 11 or more (drug and buffering agents) were used in test formulations.
Carrier/vehicle/solvent used in the suspension of the present invention includes aqueous and non-aqueous carriers but are not limited to water, alcohol, polyethylene glycol, propylene glycol, glycerin, oil, or combinations thereof. Oils include peanut oil, soy bean oil, corn oil, sesame oil, cottonseed oil, acetylated glycerides, ethyl oleate, mineral oil, fatty acid esters, mono- or di- fatty acid esters of polyethylene glycols, or glyceryl mono-oleate. Particularly, the suspensions are aqueousbased. By “aqueous carrier” is meant a suspension comprising water, or a combination of water and a water-miscible organic solvent or solvents. Water-miscible solvents include but are not limited to propylene glycol, polyethylene glycol and ethanol. “Non-aqueous carrier” comprises a suspension in which the carrier does not include water. The carrier can also include one more pharmaceutically
acceptable excipients which can be in dissolved or dispersed form. The carrier is present in an amount from about 5% to about 99%, particularly from about 40% to about 95% w/w or w/v.
The suspending agent enhances the physical stability of the composition by sufficiently increasing the viscosity so that an appropriate dose can be delivered with minimal shaking. Suitable suspending agents/viscosity agents are selected from the group comprising cellulose derivatives such as hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, methylcellulose, carboxymethyl cellulose and its salts/derivatives, e.g., carboxymethyl cellulose sodium, microcrystalline cellulose, and co-processed spray dried forms of microcrystalline cellulose and carboxymethyl cellulose sodium (such as Avicel® RC-501, Avicel® RC-581, Avicel® RC-591, and Avicel®CL-611); carbomers (available under the trade name Carbopol®); gums such as xanthan gum, locust bean gum, tragacanth gum, arabinogalactan gum, agar gum, gellan gum, guar gum, apricot gum, karaya gum, sterculia gum, acacia gum, gum arabic, and carrageenan; pectin; propylene glycol alginate, dextran; gelatin; polyethylene glycols; polyvinyl compounds such as polyvinyl acetate, polyvinyl alcohol, and polyvinyl pyrrolidone; starch; and mixtures thereof. The suspending agents are present in an amount of about 0.05% to about 20% w/w or w/v of the composition. Particularly, the suspending agents are present in an amount of about 0.1% to about 10%, about 0.1% to about 5% and about 0.1% to about 3% w/w or w/v of the composition.
The suspension is easily pourable and when shaken has a viscosity in the range of 100 cps (centipoise) to 10000 cps at 25°C. Particularly, the viscosity is in the range of 100 cps to 5000 cps at 25°C, 100 cps to 2500 cps at 25°C, 100 cps to 1500 cps at 25°C, 300 cps to 4000 cps at 25°C. More particularly, the viscosity is in the range of 100 cps to 4000 cps at 25°C.
The term “shaken” as used herein refers to shaken prior to use, e.g. by a patient, e.g. vigorously shaken, e.g. by hand, e.g. for 5 to 60 seconds.
The viscosity can be measured by using a suitable instrument such as Brookfield viscometer, Haake VT 550 viscometer at room temperature (25°C).
Various useful fillers or diluents include, but are not limited to sugars (e.g. sucrose, dextrose, fructose, lactose, maltose, invert sugar), sugar alcohols (e.g. sorbitol, mannitol, xylitol, lactitol, erythritol, maltodextrin, maltitol, isomaltitol, isomalt, maltulose, isomaltulose, lactulose, threitol, arabitol, ribitol, galactitol), starch, pregelatinized starch, calcium carbonate, calcium phosphate, dibasic anhydrous, calcium phosphate, dibasic dihydrate, calcium phosphate tribasic, calcium sulphate, cellulose powdered, silicified microcrystalline cellulose, cellulose acetate, magnesium
carbonate, magnesium oxide, microcrystalline cellulose, polydextrose, sodium alginate, sodium chloride and or mixtures thereof. The diluent is present in an amount of 5% to 99% w/w of the total composition.
In accordance with another embodiment of the present invention, sucrose has a particle size such that not less than 90% of particles are below 200 pm. In particular, sucrose has a particle size such that not less than 90% of particles are below 100 pm. This helps in achieving improved uniformity of the drug in the mixture.
Various useful pH adjusting agent/ buffering agents include, but are not limited to, citrate buffers, phosphate buffers, or any other suitable buffer known in the art including monosodium dibasic phosphate, gluconic acid, lactic acid, citric acid, acetic acid, sodium gluconate, sodium lactate, sodium citrate, sodium acetate potassium citrate, sodium bicarbonate, potassium bicarbonate, sodium dihydrogen phosphate and potassium dihydrogen phosphate. The pH adjusting agents are present in an amount of about 0.1% to about 8% w/w or w/v of the composition.
The amount of surfactant or wetting agent should be sufficient to facilitate the dispersion of riociguat in the suspension. At the same time, it should provide improved wettability of the riociguat. Suitable surfactant or wetting agents are selected from the group comprising non-ionic, anionic, cationic, or zwitterionic surfactants, and combinations thereof. Suitable examples of surfactants are sodium lauryl sulphate; cetrimide; polyethylene glycols; polyglycerin fatty acid esters such as decaglyceryl monolaurate and decaglyceryl monomyristate; sorbitan fatty acid esters such as sorbitan monostearate; polyoxyethylene sorbitan fatty acid esters such as polyoxyethylene sorbitan monooleate; polysorbates (such as polysorbate 80); polyoxyethylene alkyl ether such as polyoxyethylene lauryl ether; polyoxyethylene castor oil; polyoxyethylene -polyoxypropylene block copolymers such as poloxamers (e.g. Poloxamer 188); polyoxyethylene stearate such as polyoxy 100 stearate (Myrj® 59P) as the wetting agent and combinations thereof. Particularly, surfactant or wetting agents are non-ionic. The surfactant or wetting agents are present in an amount of about 0.01% to about 8% w/w or w/v of the composition. Particularly, the surfactant or wetting agents are present in an amount of about 0.01% to about 3%, and more particularly from about 0.01% to about 1% w/w or w/v of the composition.
Various useful preservatives include, but are not limited to, parabens such as methylparaben, propylparaben, butylparaben and their salts, sorbic acid, sodium sorbate, potassium sorbate, calcium sorbate, benzoic acid, sodium benzoate, potassium benzoate, calcium benzoate, methyl
hydroxybenzoate, ethyl para-hydroxybenzoate, sodium ethyl para-hydroxybenzoate, sodium metabisulphite, chlorhexidine, diazolidinyl urea, sodium citrate, butylated hydroxyl toluene (BHT), butylated hydroxyl anisole (BHA), tocopherol, ethylenediamine tetraacetic acid, propyl gallate, quaternary compounds, e.g. benzalkonium chloride and cetylpyridinium chloride, phenyl ethyl alcohol and combinations thereof. In particular, the preservative is selected from benzoic acid and its salts and parabens. The preservative is present in an amount of about 0.001% to about 3% w/w or w/v of the composition.
Various useful anticaking agents/glidants include, but are not limited to, colloidal silica and/or colloidal silicon dioxide (e.g. Aerosil® 200), magnesium trisilicate, calcium phosphate tribasic, magnesium oxide, magnesium silicate, calcium silicate, talc and combinations thereof. The anticaking agents are present in an amount of about 0.1% to about 10% w/w of the composition. More particularly, the anticaking agents are present in an amount of about 0.5% to about 7% w/w of the composition.
Various useful antioxidants include, but are not limited to, ascorbic acid, tertbutylhydroquinone, sodium pyrosulfite, glutathione, sodium bisulfite, sodium sulfite, a-tocopherol, a-tocopherol acetate, monothioglycerol, cysteine, ascorbyl palmitate, acetylcysteine, dithiothreitol, sodium metabisulfite, thiourea, sodium thiosulfate, butylated hydroxyl anisole (BHA), butylated hydroxytoluene (BHT) and propyl gallate The antioxidant is present in an amount from 0% to about 20%, from about 0.001% to about 5% w/w or w/v.
Various useful sweetening agents include, but are not limited to, sugars such as sucrose, dextrose, fructose, lactose, maltose, invert sugar, sugar alcohols such as sorbitol, mannitol, xylitol, lactitol, erythritol, maltodextrin, maltitol, isomaltitol, isomalt, maltulose, isomaltulose, lactulose, threitol, arabitol, ribitol, galactitol, and sugar substitutes such as saccharin sodium, aspartame, acesulfame, and sucralose. Sugar or a sugar alcohol can also act as a filler. The sweetening agents are present in an amount of 0% to about 90% w/w or w/v of the composition, particularly in an amount of about 0.1% to about 90% w/w or w/v of the composition, more particularly in an amount of about 0.1% to about 30% w/w or w/v of the composition.
Various useful flavoring agents include, but are not limited to, flavors such as banana, lemon, orange, grape, lime and grapefruit, vanilla, bubble gum, peppermint, tutti-frutti, and fruit essence, including apple, banana, pear, peach, strawberry, raspberry, cherry, plum, pineapple, apricot;
synthetic flavor oils and flavoring aromatics and/or natural oils, extracts from plant leaves, flowers, fruits such as cinnamon oil, oil of Wintergreen, peppermint oils, clove oil, citrus oil, bay oil, anise oil, eucalyptus, thyme oil, cedar leaf oil, oil of nutmeg, oil of sage, oil of bitter almonds, and cassia oil; maltol, ethyl vanillin, menthol, citric acid, fumaric acid, ethyl maltol, and tartaric acid and combinations thereof. The flavoring agents are present in an amount of about 0.1% to about 5% w/w or w/v of the composition.
Various useful lubricants include, but are not limited to magnesium stearate, calcium stearate, stearic acid, and sodium stearyl fumarate. The lubricants are present in an amount of about 0.1% to about 5% w/w based on the total weight of the powder formulation.
Suitable binders are selected from the group comprising gums such as guar gum, acacia, alginic acid, sodium alginate; carbomers; dextrin; maltodextrin; celluloses e.g., methylcellulose, ethyl cellulose, hydroxethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, hydroxyethylmethyl cellulose, carboxymethyl cellulose sodium; povidone; dextrose; polydextrose, starch, pregelatinized starch, microcrystalline cellulose, polymethacrylates including acrylic copolymers, gelatin, and mixture thereof. The binder is present in an amount of about 0.1% w/w to about 30% w/w of the composition.
Various useful taste-masking agents include, but are not limited to, water soluble and/or insoluble polymeric excipient, water insoluble non-polymeric excipient, adsorbent, ion exchange resin, carbomer, alkali metal chlorides or an alkaline earth metal chlorides or a derivative thereof.
Various useful antifoaming agents include, but are not limited to simethicone.
Suitable coloring agents are selected from the group comprising FD&C (Federal Food, Drug and Cosmetic Act) approved coloring agents; natural coloring agents; natural juice concentrates; pigments such as iron oxide, titanium dioxide, and zinc oxide; and combinations thereof.
The pharmaceutical composition of the present invention can be packaged in a suitable pack/container such as amber-colored polyethylene terephthalate (PET) bottle, glass bottle, vials, high density polyethylene (HDPE) bottle, low density polyethylene (LDPE) bottle, polypropylene (PP) bottle, packets, pouches, sachets and the like. The glass or plastic bottle is provided with a child proof closure. The package can include a syringe (marked in mL) for ease of dosing. The suspension powder formulation can be for a single dose or multiple doses after reconstitution with a carrier.
The container such as bottle has a fill volume of, e.g., from about 20 mL to about 300 mL comprising riociguat suspension. Pack chosen are made of material which is non-reactive with the
suspension and suspension powder for reconstitution. Containers for use in the storage of the oral suspensions may be used to administer a multiple dose of riociguat.
The suspension powder for reconstitution can be provided in a kit comprising (a) suspension powder for reconstitution of riociguat and (b) a pharmaceutically acceptable carrier.
In accordance with yet another embodiment of the present invention, there is provided a suspension comprising riociguat, wherein the suspension is provided in a kit comprising: (a) an immediate release oral pharmaceutical ready to use suspension comprising riociguat, and (b) a dosing syringe for administering the suspension.
The suspensions of the present invention are homogenous and deliver the desired dose of riociguat in every use without any risk of overdosing or underdosing. The compositions provide predictable riociguat release throughout the shelf life. pH Measurement: pH values are determined using potentiometry using USP <791>.
Viscosity Measurement: The viscosity can be measured by using a suitable instrument such as Brookfield viscometer, Haake VT 550 viscometer at room temperature (25°C).
Dissolution studies
The powder for suspension was evaluated for in-vitro riociguat release. The in-vitro dissolution is determined using a USP type II apparatus at 75 rpm in 900 mL of pH 6.8 phosphate buffer with 0.1% sodium lauryl sulfate at 37±0.5°C by HPLC method.
The invention may be further illustrated by the following examples, which are for illustrative purposes only and should not be construed as limiting the scope of the invention in any way.
EXAMPLES
Process: Dry granulation/ Wet granulation/ Dry blending
The suspension powder for reconstitution is reconstituted with a suitable carrier such as water when required.
Example 12-15. Ready-To-Use Suspension of riociguat
Procedure: Suitable sweetener/diluent was added to the purified water and was stirred to get a clear solution. Suitable suspending agent was added to the solution and was stirred for a suitable time (30 minutes). A suitable buffer solution was prepared by adding pH-adjusting agents in purified water and was added to the dispersion. Suitable wetting agents and riociguat were added in the dispersion and were stirred for a suitable time period. Suitable preservatives (methylparaben and propylparaben) were added in a suitable carrier such as glycerin (heated at 80°C) and were cooled at room temperature and were added to the suspension (example 13-14) or sodium benzoate was added in to the suspension (example 15). Suitable sweetening and flavoring agents were added to the suspension and were stirred for a suitable time. Suspension was homogenized for a suitable time period. Volume of suspension was adjusted with a suitable liquid carrier and was stirred the final suspension for a suitable time (30 minutes). The suspension was filled into a suitable container closure system.
Results: The dissolution, pH and assay of dosage forms prepared using quantitative formula is given below. The dissolution profile was measured in 900 ml of 6.8 phosphate buffer and 0.1%
sodium lauryl sulfate (SLS) using a USP II apparatus (Paddle) at a temperature of 37±0.5°C and a rotation speed of 75 revolutions per minute. The test examples exhibited desired pharmaceutical formulation technical attributes such as dissolution profile, pH, and assay. Test formulations pH was determined in the range of 3-7.
Claims
1. An immediate release oral pharmaceutical suspension dosage form comprising: a) riociguat in an amount of about 0.01 % to about 30% w/v of the dosage form; b) a suspending agent selected from xanthan gum, mixture of microcrystalline cellulose and sodium carboxymethyl cellulose, propylene glycol alginate, and gellan gum in an amount from about 0.05% to about 20% w/v of the dosage form; c) a wetting agent selected from poloxamer, polysorbate, polyoxyethylene stearate and combination thereof in an amount from about 0.01% to about 5% w/v of the dosage form; d) pH adjusting agent selected from citric acid, trisodium citrate, citrate buffer, monosodium dibasic phosphate, tribasic sodium phosphate and combination thereof in an amount from about 0.01% to about 5% w/v of the dosage form; e) a pharmaceutically acceptable liquid carrier selected from water, glycerin, and combination thereof in an amount from about 10% to about 95% w/v of the dosage form; and f) at least one or more other pharmaceutically acceptable excipients; wherein the pH of the suspension is from 3 to 7.
2. The immediate release oral pharmaceutical suspension dosage form of claim 1, wherein the viscosity of the suspension is from about 100 cps to about 3000 cps.
3. The immediate release oral pharmaceutical suspension dosage form of claim 1, wherein the suspension dosage form is a ready to use suspension.
4. The immediate release oral pharmaceutical suspension dosage form of claim 1, wherein the amount of riociguat in the suspension ranges from about 0.05 mg/mL to about 30 mg/mL.
5. The immediate release oral pharmaceutical suspension dosage form of claim 1, wherein the amount of riociguat in the suspension ranges from about 0.05 mg/mL to about 5 mg/mL.
6. The immediate release oral pharmaceutical suspension dosage form of claim 1, wherein the riociguat and suspending agent have a ratio ranging from about 1:0.01 to 1:40.
7. The immediate release oral pharmaceutical suspension dosage form of claim 1, wherein the riociguat and suspending agent have a ratio ranging from about 1:0.01 to 1:25.
8. The immediate release oral pharmaceutical suspension dosage form of claim 1, wherein the riociguat and wetting agent have a ratio ranging from about 1:0.01 to 1:5.
26
9. The immediate release oral pharmaceutical suspension dosage form of claim 1, wherein the one or more other pharmaceutically acceptable excipients are selected from the group comprising of antioxidant, anticaking agent, antifoaming agent, coloring agent, sweetening agent, flavouring agent, diluent, carrier, glidant, binder, and preservative.
10. The immediate release oral pharmaceutical suspension dosage form of claim 1, wherein the pH of the dosage form is 4 to 6.
11. A process for the preparation of immediate release oral pharmaceutical suspension dosage form of claim 1, wherein the suspension dosage form is prepared by mixing, blending, dry granulation, wet granulation, hot-melt extrusion process, extrusion spheronization, fluidized bed granulation, dispersion or homogenization.
12. The immediate release oral pharmaceutical suspension dosage form of claim 1, wherein the dosage form further comprises one or more sweetening agents selected from the group consisting of sucrose, dextrose, sucralose, sorbitol, fructose, mannitol, saccharin sodium, aspartame, thaumatin and combination thereof in an amount of about 0.1% to about 20% of the dosage form.
13. The immediate release oral pharmaceutical suspension dosage form of claim 1, wherein the dosage form further comprises one or more preservatives selected from the group consisting of parabens such as methylparaben, propylparaben, butylparaben benzoic acid, sodium benzoate, potassium benzoate, butylated hydroxyl toluene, butylated hydroxyl anisole, tocopherol, benzalkonium chloride and combination thereof in an amount of about 0.001 % to about 3% of the dosage form.
14. The immediate release oral pharmaceutical suspension dosage form of claim 1, wherein the dosage form further comprises one or more flavoring agents selected from the group consisting of orange, grape, lime, vanilla, bubble gum, peppermint, tutti-frutti, strawberry, and combination thereof in an amount of about 0.01% to about 5% of the dosage form.
15. The immediate release oral pharmaceutical suspension dosage form of claim 1, wherein the dosage form is provided in a kit comprising (a) a ready to use suspension comprising riociguat, and (b) a dosing syringe for administering the suspension.
16. An immediate release oral pharmaceutical ready to use suspension dosage form comprising: a) riociguat in an amount of about 0.01% to about 5% w/v of the dosage form; b) a suspending agent selected from xanthan gum, mixture of microcrystalline cellulose and
sodium carboxymethyl cellulose, propylene glycol alginate, and gellan gum in an amount from about 0.05% to about 3% w/v of the dosage form; c) a wetting agent selected from poloxamer, polysorbate, polyoxyethylene stearate and combination thereof in an amount from about 0.01% to about 2% w/v of the dosage form; d) liquid carrier selected from water, glycerin and combination thereof in an amount from about 10% to about 95% w/v of the dosage form; and e) at least one or more other pharmaceutically acceptable excipients; wherein the pH of the suspension is from 3 to 6 and suspension exhibits an in-vitro dissolution rate of more than 85% of drug release within 30 minutes when measured in 900 ml of 6.8 phosphate buffer and 0.1% sodium lauryl sulfate using a USP II apparatus (Paddle) at a temperature of 37±0.5°C and a rotation speed of 75 revolutions.
17. An immediate release oral pharmaceutical ready to use suspension dosage form comprising: a) riociguat in an amount of about 0.01% to about 5% w/v of the dosage form; b) a suspending agent selected from xanthan gum, mixture of microcrystalline cellulose and sodium carboxymethyl cellulose, propylene glycol alginate, and gellan gum in an amount from about 0.05% to about 3% w/v of the dosage form; c) a wetting agent selected from poloxamer, polysorbate, polyoxyethylene stearate and combination thereof in an amount from about 0.01% to about 2% w/v of the dosage form; d) citric acid in an amount from about 0.01% to about 2% w/v of the dosage form; e) trisodium citrate in an amount from about 0.01% to about 2% w/v of the dosage form; f) sorbitol in an amount from about 0.01% to about 11% w/v of the dosage form; g) methylparaben and/or propylparaben in an amount from about 0.01% to about 1% w/v of the dosage form; and h) liquid carrier selected from water, glycerin and combination thereof in an amount from about 10% to about 95% w/v of the dosage form; wherein the pH of the suspension is from 3 to 6 and the riociguat and suspending agent have a ratio ranging from about 1:0.01 to 1:25.
18. The immediate release oral pharmaceutical ready to use suspension dosage form of claim
17, wherein the dosage form further comprises one or more flavoring agents in an amount from about 0.01 % to about 1 % w/v of the dosage form.
19. An immediate release oral pharmaceutical ready to use suspension dosage form comprising: a) riociguat in an amount of about 0.05 mg/mL to about 7.5 mg/mL of the dosage form; b) a suspending agent selected from xanthan gum, mixture of microcrystalline cellulose and sodium carboxymethyl cellulose, propylene glycol alginate, and gellan gum in an amount from about 0.1 mg/ml to about 10 mg/ml of the dosage form; c) a wetting agent selected from poloxamer, polysorbate, polyoxyethylene stearate and combination thereof in an amount about 0.01 mg/ml to about 5 mg/ml of the dosage form; d) pH adjusting agent selected from citric acid, trisodium citrate, citrate buffer, monosodium dibasic phosphate, tribasic sodium phosphate and combination thereof in an amount from about 0.01 mg/ml to about 5 mg/ml of the dosage form; and e) a pharmaceutically acceptable liquid carrier selected from water, glycerin and combination thereof in an amount up to 1ml for 1ml suspension dosage form; wherein the pH of the suspension is from 3 to 6 and wherein riociguat has a particle size distribution D90 less than about 20 pm. 0. The immediate release oral pharmaceutical ready to use suspension dosage form of claim 19, wherein the suspension comprises less than 2% of total impurities and less than 0.5% of carbamate impurity.
29
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163133601P | 2021-01-04 | 2021-01-04 | |
US63/133,601 | 2021-01-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022144930A1 true WO2022144930A1 (en) | 2022-07-07 |
Family
ID=82260321
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2022/050008 WO2022144930A1 (en) | 2021-01-04 | 2022-01-04 | Pharmaceutical oral suspensions of riociguat |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022144930A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104434845A (en) * | 2014-11-12 | 2015-03-25 | 广东东阳光药业有限公司 | Riociguat-containing solid medicinal preparation |
CN105596311A (en) * | 2015-12-29 | 2016-05-25 | 郑州大明药物科技有限公司 | Riociguat oral solid preparation and preparing method thereof |
CN105878197A (en) * | 2016-03-31 | 2016-08-24 | 北京万全德众医药生物技术有限公司 | Riociguat orally disintegrating tablet and preparation method thereof |
-
2022
- 2022-01-04 WO PCT/IN2022/050008 patent/WO2022144930A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104434845A (en) * | 2014-11-12 | 2015-03-25 | 广东东阳光药业有限公司 | Riociguat-containing solid medicinal preparation |
CN105596311A (en) * | 2015-12-29 | 2016-05-25 | 郑州大明药物科技有限公司 | Riociguat oral solid preparation and preparing method thereof |
CN105878197A (en) * | 2016-03-31 | 2016-08-24 | 北京万全德众医药生物技术有限公司 | Riociguat orally disintegrating tablet and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11642351B2 (en) | Eslicarbazepine suspension | |
KR101632079B1 (en) | Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof | |
US20230381194A1 (en) | Suspension for oral administration comprising amorphous tolvaptan | |
US9161913B2 (en) | Stabilized pediatric suspension of carisbamate | |
US20070015841A1 (en) | Pharmaceutical propylene glycol solvate compositions | |
JP2020506245A (en) | Lamotrigine suspension dosage form | |
US11331324B2 (en) | Modified release suspension of eslicarbazepine | |
WO2022144930A1 (en) | Pharmaceutical oral suspensions of riociguat | |
US8492423B2 (en) | Pharmaceutical propylene glycol solvate compositions | |
US11318145B2 (en) | Eslicarbazepine suspension | |
JP2019530727A (en) | Powder for oral suspension containing lamotrigine | |
US20220265552A1 (en) | Eslicarbazepine suspension | |
US9775832B2 (en) | Pharmaceutical composition for oral administration | |
US20220273670A1 (en) | Modified release suspension of eslicarbazepine | |
EP2987482A1 (en) | Soluble and dispersible pharamaceutical deferasirox formulation | |
WO2013109230A1 (en) | Pharmaceutical compositions comprising tadalafil | |
US11890273B2 (en) | Losartan liquid formulations and methods of use | |
HUT77362A (en) | Sabeluzole aqueous oral suspensions and process for preparation of them | |
WO2022147183A1 (en) | Pharmaceutical extended release suspensions of riociguat | |
WO2020049536A1 (en) | Pharmaceutical compositions of valacyclovir or its pharmaceutically acceptable salts thereof | |
WO2023285981A1 (en) | Stable pharmaceutical liquid composition of nilotinib | |
US20230390194A1 (en) | Formulations of nebivolol | |
TW202313007A (en) | Oral aqueous suspension formulations comprising carbamate compound | |
US20230158012A1 (en) | Oral liquid formulations of lenvatinib | |
WO2020212898A1 (en) | Pharmaceutical oral liquid solution of ivacaftor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22734787 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22734787 Country of ref document: EP Kind code of ref document: A1 |